

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the biology and therapy of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-2184/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-2184" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the biology and therapy of medullary thyroid carcinoma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the biology and therapy of medullary thyroid carcinoma.">
            <meta name="og:description" content="Read the latest article version by Barry Nelkin, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="13691">
            <meta name="article-id" content="12645">
            <meta name="dc.title" content="Recent advances in the biology and therapy of medullary thyroid carcinoma">
            <meta name="dc.description" content="Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant thyroid cancer. Several recent advances in the biology and current or potential treatment of MTC are notable. These include a new understanding of the developmental biology of the thyroid C cell, which heretofore was thought to develop from the neural crest. RET, encoded by the most common driver gene in MTC, has been shown to be a dual function kinase, thus expanding its potential substrate repertoire. Promising new therapeutic developments are occurring; many have recently progressed to clinical development. There are new insights into RET inhibitor therapy for MTC. New strategies are being developed to inhibit the RAS proteins, which are potential therapeutic targets in MTC. Potential emerging immunotherapies for MTC are discussed. However, gaps in our knowledge of the basic biology of the C cell, its transformation to MTC, and the mechanisms of resistance to therapy impede progress; further research in these areas would have a substantial impact on the field.">
            <meta name="dc.subject" content="Medullary thyroid cancer, RET, Treatment, RET inhibitors, RAS inhibitors ">
            <meta name="dc.creator" content="Nelkin, Barry">
            <meta name="dc.date" content="2017/12/28">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.12645.1">
            <meta name="dc.source" content="F1000Research 2017 6:2184">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Medullary thyroid cancer">
            <meta name="prism.keyword" content="RET">
            <meta name="prism.keyword" content="Treatment">
            <meta name="prism.keyword" content="RET inhibitors">
            <meta name="prism.keyword" content="RAS inhibitors ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/12/28">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="2184">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.12645.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-2184">
            <meta name="citation_title" content="Recent advances in the biology and therapy of medullary thyroid carcinoma">
            <meta name="citation_abstract" content="Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant thyroid cancer. Several recent advances in the biology and current or potential treatment of MTC are notable. These include a new understanding of the developmental biology of the thyroid C cell, which heretofore was thought to develop from the neural crest. RET, encoded by the most common driver gene in MTC, has been shown to be a dual function kinase, thus expanding its potential substrate repertoire. Promising new therapeutic developments are occurring; many have recently progressed to clinical development. There are new insights into RET inhibitor therapy for MTC. New strategies are being developed to inhibit the RAS proteins, which are potential therapeutic targets in MTC. Potential emerging immunotherapies for MTC are discussed. However, gaps in our knowledge of the basic biology of the C cell, its transformation to MTC, and the mechanisms of resistance to therapy impede progress; further research in these areas would have a substantial impact on the field.">
            <meta name="citation_description" content="Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant thyroid cancer. Several recent advances in the biology and current or potential treatment of MTC are notable. These include a new understanding of the developmental biology of the thyroid C cell, which heretofore was thought to develop from the neural crest. RET, encoded by the most common driver gene in MTC, has been shown to be a dual function kinase, thus expanding its potential substrate repertoire. Promising new therapeutic developments are occurring; many have recently progressed to clinical development. There are new insights into RET inhibitor therapy for MTC. New strategies are being developed to inhibit the RAS proteins, which are potential therapeutic targets in MTC. Potential emerging immunotherapies for MTC are discussed. However, gaps in our knowledge of the basic biology of the C cell, its transformation to MTC, and the mechanisms of resistance to therapy impede progress; further research in these areas would have a substantial impact on the field.">
            <meta name="citation_keywords" content="Medullary thyroid cancer, RET, Treatment, RET inhibitors, RAS inhibitors ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Barry Nelkin">
            <meta name="citation_author_institution" content="Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD, 21287, USA">
            <meta name="citation_publication_date" content="2017/12/28">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="2184">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.12645.1">
            <meta name="citation_firstpage" content="2184">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-2184/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-2184.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=13691 /> <input type=hidden id=articleId name=articleId value=12645 /> <input type=hidden id=xmlUrl value="/articles/6-2184/v1/xml"/> <input type=hidden id=xmlFileName value="-6-2184-v1.xml"> <input type=hidden id=article_uuid value=ad1ff134-02c6-412a-b0fc-7dc23447bbb3 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the biology and therapy of medullary thyroid carcinoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.12645.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.12645.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-2184"
  },
  "headline": "Recent advances in the biology and therapy of medullary thyroid carcinoma",
  "datePublished": "2017-12-28T14:22:09",
  "dateModified": "2017-12-28T14:22:09",
  "author": [
    {
      "@type": "Person",
      "name": "Barry Nelkin"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant thyroid cancer. Several recent advances in the biology and current or potential treatment of MTC are notable. These include a new understanding of the developmental biology of the thyroid C cell, which heretofore was thought to develop from the neural crest. RET, encoded by the most common driver gene in MTC, has been shown to be a dual function kinase, thus expanding its potential substrate repertoire. Promising new therapeutic developments are occurring; many have recently progressed to clinical development. There are new insights into RET inhibitor therapy for MTC. New strategies are being developed to inhibit the RAS proteins, which are potential therapeutic targets in MTC. Potential emerging immunotherapies for MTC are discussed. However, gaps in our knowledge of the basic biology of the C cell, its transformation to MTC, and the mechanisms of resistance to therapy impede progress; further research in these areas would have a substantial impact on the field."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-2184.html",
            "name": "Recent advances in the biology and therapy of medullary thyroid carcinoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the biology and therapy of medullary thyroid carcinoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=13691 data-id=12645 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12645.1" data-recommended="" data-doi="10.12688/f1000research.12645.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-2184/v1/pdf?article_uuid=ad1ff134-02c6-412a-b0fc-7dc23447bbb3" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-12645-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-12645-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-12645-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2184 (<a class=new-orange href="https://doi.org/10.12688/f1000research.12645.1" target=_blank>https://doi.org/10.12688/f1000research.12645.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-12645-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=12645 id=track-article-signin-12645 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12645?target=/articles/6-2184.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13691 /> <input name=articleId type=hidden value=12645 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the biology and therapy of medullary thyroid carcinoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:bnelkin@jhmi.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Barry Nelkin</span></a><a href="https://orcid.org/0000-0002-1552-6377" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1552-6377</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:bnelkin@jhmi.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Barry Nelkin</span></a><a href="http://orcid.org/0000-0002-1552-6377" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1552-6377</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 28 Dec 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.12645.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD, 21287, USA<br/> <p> <div class=margin-bottom> Barry Nelkin <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29169-29170></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=12506-29171></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant thyroid cancer. Several recent advances in the biology and current or potential treatment of MTC are notable. These include a new understanding of the developmental biology of the thyroid C cell, which heretofore was thought to develop from the neural crest. RET, encoded by the most common driver gene in MTC, has been shown to be a dual function kinase, thus expanding its potential substrate repertoire. Promising new therapeutic developments are occurring; many have recently progressed to clinical development. There are new insights into RET inhibitor therapy for MTC. New strategies are being developed to inhibit the RAS proteins, which are potential therapeutic targets in MTC. Potential emerging immunotherapies for MTC are discussed. However, gaps in our knowledge of the basic biology of the C cell, its transformation to MTC, and the mechanisms of resistance to therapy impede progress; further research in these areas would have a substantial impact on the field. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Medullary thyroid cancer, RET, Treatment, RET inhibitors, RAS inhibitors </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Barry Nelkin (<a href="mailto:bnelkin@jhmi.edu">bnelkin@jhmi.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Barry Nelkin </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Nelkin B. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2184 (<a href="https://doi.org/10.12688/f1000research.12645.1" target=_blank>https://doi.org/10.12688/f1000research.12645.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 28 Dec 2017, <b>6</b>(F1000 Faculty Rev):2184 (<a href="https://doi.org/10.12688/f1000research.12645.1" target=_blank>https://doi.org/10.12688/f1000research.12645.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 28 Dec 2017, <b>6</b>(F1000 Faculty Rev):2184 (<a href="https://doi.org/10.12688/f1000research.12645.1" target=_blank>https://doi.org/10.12688/f1000research.12645.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d15181e137>Introduction</h2><p class="" id=d15181e140>Medullary thyroid cancer (MTC) is a relatively uncommon (about 1,400 new cases per year in the US) cancer of the thyroid C cells, yet accounts for a substantial fraction of thyroid cancer mortality. Excellent comprehensive reviews of the biology, genetics, and management of MTC have been published<sup><a href="#ref-1">1</a>–<a href="#ref-9">9</a></sup>. Briefly, in 25% of MTC cases, the disease is hereditary, occurring as part of the MEN 2 syndromes (MEN 2A, MEN 2B, and familial medullary thyroid cancer) due to germline activating mutations of the <i>RET</i> receptor tyrosine kinase gene. <i>RET</i> is also mutated in about 50% of sporadic cases of MTC; in both hereditary and sporadic cases, specific mutations are correlated with phenotype and prognosis<sup><a href="#ref-4">4</a>,<a href="#ref-6">6</a></sup>. MTC is resistant to cytotoxic chemotherapy. RET inhibitors have provided significant clinical benefit; two RET inhibitors, vandetanib and cabozantinib, are US Food and Drug Administration (FDA)-approved for the treatment of advanced MTC<sup><a href="#ref-10">10</a>–<a href="#ref-12">12</a></sup>. In this short and necessarily selective review, I discuss some recent advances in MTC and in related areas that are likely to affect MTC. I have tried to point out some other areas in which MTC research might be productively focused.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15181e173>Biology of medullary thyroid cancer</h2><div class=section><a name=d15181e176 class=n-a></a><h3 class=section-title>Medullary thyroid cancer is not derived from the neural crest</h3><p class="" id=d15181e181>For almost half a century, thyroid C cells have been thought to be derived from the neural crest. This hypothesis was based largely on chick-quail xenotransplantation studies by Le Douarin <i>et al</i>.<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>, which revealed that avian calcitonin-producing ultimobranchial bodies were derived from the neural crest. This model was extrapolated to mammalian species, in which the ultimobranchial bodies are derived from the fourth pharyngeal pouch and invade the thyroid during development, differentiating into C cells. The neural crest derivation of mammalian ultimobranchial bodies and thyroid C cells was challenged by Kameda <i>et al</i>.<sup><a href="#ref-15">15</a></sup>, who showed by cell-lineage tracing that mouse ultimobranchial bodies were not derived from neural crest cells. Recently, Johansson <i>et al</i>.<sup><a href="#ref-16">16</a></sup> used an elegant lineage-tracing scheme to confirm that mouse ultimobranchial bodies and thyroid C cells are not derived from neural crest cells but rather from pharyngeal endoderm. Nevertheless, C-cell development is significantly influenced by neural crest-derived cells<sup><a href="#ref-17">17</a></sup>. These findings may have an impact on our understanding of the biology of mixed histology tumors, as discussed by DeLellis and Mangray<sup><a href="#ref-8">8</a></sup>. While many of these are likely to be “collision tumors”, the endodermal origin of both C cells and follicular cells strengthens the possibility that some of these tumors arise from a single progenitor cell.</p></div><div class=section><a name=d15181e218 class=n-a></a><h3 class=section-title>Understanding RET</h3><p class="" id=d15181e223>A potential dramatic change in our understanding of RET kinase function is underway. Bagheri-Yarmand <i>et al</i>.<sup><a href="#ref-18">18</a></sup> reported that RET is not only a membrane-bound receptor tyrosine kinase, but also is localized to the nucleus. There, one of its functions is to inhibit the pro-apoptotic transcription factor ATF4. This antagonism of ATF4 activity provides a potential mechanism for the anti-apoptotic function of RET<sup><a href="#ref-19">19</a></sup>. Remarkably, Bagheri-Yarmand <i>et al</i>.<sup><a href="#ref-18">18</a></sup> showed that RET appears to accomplish this inhibition by <i>threonine</i> phosphorylation of ATF4, marking it for proteolytic degradation; thus, RET is a dual specificity tyrosine-threonine kinase. Plaza-Menacho <i>et al</i>.<sup><a href="#ref-20">20</a></sup> recently confirmed and extended this finding of dual specificity, showing that RET is autophosphorylated at serine 909 in the activation domain. While they show that this phosphorylation has no effect on RET enzymatic activity <i>in vitro</i>, they showed that it affects RET signaling in an <i>in vivo</i> model. In the <i>Drosophila</i> Ret2B model of MEN 2B, <i>dRet</i> M955T mutation, analogous to human <i>RET</i> M918T, results in a rough eye phenotype<sup><a href="#ref-21">21</a></sup>. When a further <i>dRet</i> S946A mutation (analogous to human S909A) was introduced, the rough eye phenotype was rescued. Plaza-Menacho <i>et al</i>.<sup><a href="#ref-20">20</a></sup> speculate that RET pS909 may function in docking of downstream effector proteins. This expanded specificity has the potential to expand the universe of substrates of RET; in any case, important RET effector substrate proteins still await identification.</p></div><div class=section><a name=d15181e286 class=n-a></a><h3 class=section-title>Under-researched area: biology of C-cell transformation</h3><p class="" id=d15181e291>Thus far, relatively little is known regarding the molecular steps of C-cell transformation leading to MTC<sup><a href="#ref-22">22</a></sup>. This is due in large part to the rarity of C cells in the normal human and mouse thyroid, limiting their study to <i>in situ</i> methods. Cell-sorting methods applied to thyroid glands<sup><a href="#ref-23">23</a>–<a href="#ref-25">25</a></sup> suggest that isolation of small numbers of normal or early dysplastic C cells may be feasible; functional and “omics” studies on such cell populations could sharply address our dearth of knowledge in this important area.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15181e312>Genomics of medullary thyroid cancer</h2><p class="" id=d15181e315>MTC cases typically have few mutations<sup><a href="#ref-26">26</a></sup>. As mentioned, about 50% of sporadic cases have an activating point mutation in the <i>RET</i> gene. The only other common mutations identified in sporadic MTC are <i>KRAS</i> and <i>HRAS</i>; <i>NRAS</i> mutations are infrequent<sup><a href="#ref-26">26</a>–<a href="#ref-31">31</a></sup>. Recent reports have described <i>ALK</i> and <i>RET</i> gene rearrangements in sporadic MTC<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. While these rearrangements are infrequent, they indicate the potential for targeted therapy in specific cases; perhaps even more importantly, they suggest the important role that these and other rearrangements may play in MTC. Rearrangements would not likely have been detected in whole exome sequencing studies of MTC<sup><a href="#ref-26">26</a></sup> and can play a dominant driver role in cancer development<sup><a href="#ref-34">34</a>–<a href="#ref-36">36</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15181e369>Treatment of medullary thyroid cancer</h2><div class=section><a name=d15181e372 class=n-a></a><h3 class=section-title>RET inhibitors: fulfilling the promise</h3><p class="" id=d15181e377><b><i>Introduction.</i></b> Vandetanib and cabozantinib have changed the face of MTC systemic therapy, offering an effective targeted treatment. Nevertheless, both drugs are effective in less than half of patients with MTC and have significant adverse effects, and (even in responsive cases) resistance develops, typically within a few years.</p><p class="" id=d15181e383><i>Adverse effects</i>. It is not clear which effects are off-target (non-RET) and which are on-target (due to RET inhibition). Since both vandetanib and cabozantinib are multikinase inhibitors, there is some thought that more specific inhibitors may alleviate these effects. However, it is necessary to consider the possibility that the inhibition of some of the other kinases targeted by these drugs contributes to their efficacy. The response of <i>RET</i> wild-type (wt) tumors may suggest that this occurs; the ability of both vandetanib and cabozantinib to inhibit VEGFR2 suggests it as a potential candidate target, in which case VEGFR2-dependent adverse effects may be inseparable from efficacy.</p><p class="" id=d15181e391><i>Resistance</i>. As mentioned above, MTC commonly exhibits intrinsic resistance to RET inhibitors, and even those cases that are initially sensitive to RET inhibitors almost always develop acquired resistance, resulting in disease progression. A critical need in the field is an understanding of the mechanisms of intrinsic and acquired resistance to RET inhibitors in MTC. Numerous mechanisms for resistance to tyrosine kinase inhibitors (TKIs) have been described, including feedback signaling response, secondary mutations, or gene amplification in the TKI, bypass activation of other signaling or survival pathways, and pharmacokinetic/pharmacodynamic (PK/PD) issues; several resistance mechanisms can coexist in a single resistant tumor<sup><a href="#ref-37">37</a></sup>. Mathematical modeling of resistance in other cancers has shown that even apparently acquired resistance may exist intrinsically as subclonal cell populations within the tumor, and such resistant cells can be selected by treatment<sup><a href="#ref-38">38</a>–<a href="#ref-40">40</a></sup>. That an understanding of the mechanisms of resistance can direct subsequent effective therapeutic strategies is not only intuitive; it has been demonstrated dramatically in many instances for TKIs and other targeted therapeutics<sup><a href="#ref-41">41</a>–<a href="#ref-46">46</a></sup>.</p><p class="" id=d15181e414>Some information regarding resistance to vandetanib and cabozantinib is available, but much further study is urgently needed. Both inhibitors perform poorly on <i>RET</i> mutants with V804M or V804L mutations<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>; these mutations are orthologous to the <i>BCR-ABL</i> T315I “gatekeeper” mutation which confers resistance to imatinib in chronic myelogenous leukemia<sup><a href="#ref-49">49</a></sup>. A recent article identified <i>RET</i> I788N as another mutation conferring resistance to cabozantinib and vandetanib<sup><a href="#ref-50">50</a></sup>; I788 is an ortholog of the V654 residue in c-<i>KIT</i>, mutation of which confers resistance to imatinib<sup><a href="#ref-51">51</a></sup>. PK studies of vandetanib and cabozantinib have been extensive. There is limited bioavailability <i>in vivo</i> and this is due in part to substantial plasma protein binding (92–94% for vandetanib<sup><a href="#ref-52">52</a></sup> and more than 99.7% for cabozantinib<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>). This suggests that resistance may be due in part to limited drug exposure within the tumor. Unfortunately, PD studies in patients treated with these compounds, pivotal for our understanding, have not been reported.</p><p class="" id=d15181e464>Remarkably, changes in MTC seen on progression after TKI therapy have not yet been reported. Such studies have been uniquely informative in identifying mechanisms of resistance to other therapeutics<sup><a href="#ref-41">41</a>–<a href="#ref-46">46</a></sup>. In such studies, progression biopsies are compared with pretreatment samples by using next-generation sequencing to look for secondary mutations, amplifications, and other genomic changes, transcriptomic studies such as RNA-seq, or proteomic studies to look for potential gene expression changes and pathway activation that may account for acquired resistance. Given the experience with disease progression on current TKIs and the facile availability of these technologies, one would hope that these elucidating correlative studies soon become standard.</p><p class="" id=d15181e474><b><i>Cabozantinib: who benefits?</i></b> In the Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) phase 3 clinical trial of cabozantinib<sup><a href="#ref-12">12</a></sup>, MTC patients receiving the drug had a significantly longer progression-free survival (PFS) than patients receiving the placebo control (median PFS 49 versus 17 weeks; hazard ratio [HR] = 0.28, <i>p</i> &lt;0.0001). Recent correlative subgroup analysis indicated that patients with a <i>RET</i> M918T mutation significantly benefited from cabozantinib treatment<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. All other mutational subgroups (<i>RET</i> non-M918T mutation, RAS mutation, RAS wt, <i>RET</i> and RAS wt, <i>RET</i> unknown status, and <i>RET</i> mutation of unknown significance) also exhibited decreased HR in response to cabozantinib treatment; the PFS differences in these subgroups did not reach statistical significance, although in some cases this was likely due to the small size of the subgroups. As the authors note, the effects of cabozantinib in these smaller subgroups will need to be resolved in future prospective studies. Notably, the M918T subgroup was the only group to exhibit a significant increase in overall survival (OS) (44.3 versus 18.9 months; HR = 0.60, <i>p</i> &lt;0.03). Thus, it is clear that cabozantinib is effective for MTC patients with the <i>RET</i> M918T mutation, but in no case is it yet possible to exclude patients from cabozantinib treatment on the basis of mutation status, especially given the paucity of effective MTC treatments other than RET multikinase inhibitors.</p><p class="" id=d15181e516>If, as suggested by the correlative data in the EXAM trial, MTC with <i>RET</i> M918T mutations derives more clinical benefit from cabozantinib than do other MTC subgroups, what might be the mechanism? Here, our understanding is impeded by our limited knowledge of the biology of <i>RET</i> mutations. A few transcriptomic studies have compared MTC cases with <i>RET</i> M918T mutations versus other <i>RET</i> mutations<sup><a href="#ref-57">57</a>–<a href="#ref-60">60</a></sup>, but further work is necessary, since some of the studies were underpowered and consensus among other studies was lacking. One potentially important difference between M918T and other <i>RET</i> mutations is in substrate specificity. RET M918T has a relaxed and altered substrate preference<sup><a href="#ref-61">61</a></sup>. This is due to destabilization of the substrate recognition domain, which also leads to increased kinase activity<sup><a href="#ref-62">62</a>–<a href="#ref-64">64</a></sup>. Speculatively, this altered kinase activity could lead to greater oncogene addiction, which would result in augmented clinical activity of RET inhibitors.</p><p class="" id=d15181e553>By what mechanism might cabozantinib provide benefit to MTC cases without RET mutations? The potential for other kinase targets of cabozantinib (including VEGFR2, MET, TIE2, RON, and others)<sup><a href="#ref-65">65</a></sup> to contribute to angiogenesis<sup><a href="#ref-65">65</a></sup>, malignant transformation<sup><a href="#ref-66">66</a></sup>, or other MTC functions has been discussed<sup><a href="#ref-55">55</a></sup>. The possibility also exists that wt RET is important in the biology of MTC.</p><p class="" id=d15181e572><b><i>New RET inhibitors.</i></b> Several new RET inhibitors have been reported<sup><a href="#ref-67">67</a></sup>. Some of these compounds have been designed for increased potency, increased specificity (especially as compared with KDR inhibition), improved PKs, or the ability to inhibit RET gatekeeper mutants. The following four interesting compounds are currently in clinical trials.</p><p class="" id=d15181e582>Alectinib (Roche) is an ALK inhibitor approved for ALK-rearranged non-small cell lung cancer. It is highly specific, inhibiting little other than ALK and RET (concentration resulting in inhibition of 50% of activity [IC<sub>50</sub>] for RET = 4.8 nM)<sup><a href="#ref-68">68</a></sup>. At somewhat higher concentrations, alectinib also effectively targets the RET gatekeeper mutants, V804L (32 nM) and V804M (53 nM). While alectinib effectively reduced phospho-RET levels in MTC cell (TT) xenografts, it had little effect on MTC xenograft growth<sup><a href="#ref-68">68</a></sup>. This suggests that another target, in addition to RET, may serve to maintain growth in MTC cells. Whether this intrinsic resistance will be seen clinically in MTC is unknown but should be determined shortly; a phase 1 trial for alectinib in MTC and other RET-driven thyroid and lung cancers (NCT03131206) is ongoing.</p><p class="" id=d15181e597>BLU-667 (Blueprint Medicines) inhibits RET at subnanomolar concentrations<sup><a href="#ref-69">69</a></sup>. It efficiently inhibits the RET V804M gatekeeper mutant at similar concentrations and has 70-fold specificity versus KDR. It is in a phase 1 clinical trial (NCT03037385) for cancers with activating <i>RET</i> gene alterations, including MTC.</p><p class="" id=d15181e607>LOXO-292 (Loxo Oncology) inhibits RET at nanomolar concentrations<sup><a href="#ref-70">70</a></sup>. It also inhibits the RET gatekeeper mutant at similar concentrations. Importantly, LOXO-292 has been shown to be very specific for RET in kinase assays. Its efficacy in inhibiting the growth of MTC cell xenografts further confirms that targeting RET alone is a viable therapeutic strategy in MTC. LOXO-292 is in a phase 1 clinical trial (NCT03157128) for cancers with activating <i>RET</i> gene alterations, including MTC.</p><p class="" id=d15181e617>RXDX-105 (Ignyta) was originally developed as a BRAF inhibitor (IC<sub>50</sub> = 14 nM)<sup><a href="#ref-71">71</a></sup>. It also efficiently inhibits wt RET (IC<sub>50</sub> = 1.5 nM)<sup><a href="#ref-71">71</a></sup>. This suggests the potential for RXDX-105 to act as a combination treatment, targeting RET and the RAF-MEK-ERK pathway, a combination which may be synergistic in MTC cells (<a href="#ref-72">72</a> and unpublished results). RXDX-105 is reported to have 96–100% bioavailability<sup><a href="#ref-71">71</a></sup>, a substantial improvement over other RET inhibitors. However, while RXDX-105 does not inhibit KDR, it is a broad-specificity inhibitor<sup><a href="#ref-71">71</a></sup>, so it may have significant adverse effects. Moreover, since it does not have activity against CRAF, one can envision “paradoxical activation” of the RAF-MEK-ERK pathway<sup><a href="#ref-73">73</a>–<a href="#ref-75">75</a></sup>. Nevertheless, in an ongoing phase 1 trial of RXDX-105 for RET-driven solid tumors (NCT01877811), a partial response was noted in a lung adenocarcinoma patient with a RET gene rearrangement<sup><a href="#ref-76">76</a></sup>.</p></div><div class=section><a name=d15181e658 class=n-a></a><h3 class=section-title>RAS as a therapeutic target in medullary thyroid cancer</h3><p class="" id=d15181e663>The discovery of RAS mutations in MTC<sup><a href="#ref-26">26</a>–<a href="#ref-31">31</a></sup> highlighted the possibility of targeting RAS therapeutically in some cases of MTC; since RET signaling functions in part through RAS activation<sup><a href="#ref-77">77</a></sup>, RAS inhibition also may be a potential therapeutic strategy in MTC with RET mutations. However, RAS has a long history as an intractable target<sup><a href="#ref-78">78</a>–<a href="#ref-80">80</a></sup>. It was realized early that targeting RAS-guanosine triphosphate (RAS-GTP) interaction would be difficult since GTP has picomolar affinity for RAS while GTP is present at millimolar concentrations in cells<sup><a href="#ref-81">81</a></sup>. A substantial effort to block RAS attachment to the cell membrane by blocking farnesyltransferase was unsuccessful because of alternative cellular mechanisms (geranylgeranylation) of membrane attachment<sup><a href="#ref-78">78</a>,<a href="#ref-79">79</a>,<a href="#ref-82">82</a>–<a href="#ref-84">84</a></sup>. Blocking RAS downstream signaling has been attractive but has commonly suffered from ineffectiveness of blocking one pathway and toxicity of blocking multiple pathways<sup><a href="#ref-85">85</a></sup>. In recent years, with advances in drug and protein biochemistry, there has been renewed interest and preclinical success in directly inhibiting RAS via a multitude of novel strategies, including small-molecule binding, inhibition of protein interactions, and antisense approaches<sup><a href="#ref-86">86</a>–<a href="#ref-111">111</a></sup>. A review of this rapidly advancing field, other than the several examples below, is outside the scope of this review, and the reader is directed to the cited references. In addition, it must be noted that some of the promising therapeutic approaches target specific RAS mutations; at least one of these targeted mutations, KRAS G12C<sup><a href="#ref-87">87</a>,<a href="#ref-91">91</a>,<a href="#ref-92">92</a>,<a href="#ref-95">95</a>,<a href="#ref-100">100</a></sup>, is rarely found in MTC<sup><a href="#ref-31">31</a></sup>.</p><p class="" id=d15181e733><b><i>PDE6δ inhibitors.</i></b> The prenyl-binding chaperone protein PDE6δ is necessary for RAS membrane localization<sup><a href="#ref-111">111</a></sup>. Early PDE6δ inhibitors, including deltarasin and deltazinone, had low nanomolar affinity for PDE6δ but required micromolar concentrations for RAS inhibitory activity in intact cells<sup><a href="#ref-88">88</a>,<a href="#ref-99">99</a></sup>. This discrepancy was recently reported to be due to inhibitor release mediated by the release factor Arl2<sup><a href="#ref-104">104</a></sup>. Newly designed PDE6δ inhibitors with subnanomolar affinity have been shown to be effective in cells and can block KRAS-dependent cell proliferation<sup><a href="#ref-104">104</a></sup>. A third generation of highly specific PDE6δ inhibitors covalently binds the active site of PDE6δ, rendering these compounds refractory to Arl2-mediated release<sup><a href="#ref-105">105</a></sup>.</p><p class="" id=d15181e762><b><i>Farnesyltransferase inhibition.</i></b> As mentioned above, the farnesyltransferase inhibitors (FTIs) failed because of alternative prenylation of RAS proteins. However, <i>HRAS</i>, the most commonly mutated RAS gene in MTC, cannot employ this alternative prenylation strategy and is dependent upon farnesyltransferase for activity. Thus, HRAS-driven cancers should be sensitive to FTIs. This hypothesis is being tested in a phase 2 study of the FTI tipifarnib for HRAS mutant thyroid or head and neck cancers (NCT02383927). Interestingly, a phase 1 clinical trial of a combination of the FTI tipifarnib and the multikinase (including RET) inhibitor sorafenib showed significant activity for MTC with or without RET mutations; HRAS mutation status was not evaluated<sup><a href="#ref-112">112</a></sup>. While the response rate was greater than that seen in another trial employing sorafenib alone<sup><a href="#ref-113">113</a></sup>, the trials were not powered for statistical comparison. If this combination is effective, it may be due to additional targets of tipifarnib<sup><a href="#ref-112">112</a></sup>, or to synergistic pathway inhibition by tipifarnib and sorafenib, similar to the synergy reported in studies of sorafenib and the MEK inhibitor selumetinib in MTC cells <i>in vitro</i><sup><a href="#ref-72">72</a></sup>.</p><p class="" id=d15181e790><b><i>Farnesyltransferase-mediated delivery of covalent RAS inhibitors.</i></b> In this recently reported, very novel approach, endogenous farnesyltransferase activity was hijacked to mislocalize KRAS by blocking normal prenylation mediated by both farnesyltransferase and geranylgeranyltransferase<sup><a href="#ref-106">106</a></sup>. Thus, a farnesyltransferase neosubstrate was designed that binds covalently to the RAS CAAX moiety yet does not promote membrane localization. In cell culture, treatment with this neosubstrate resulted in decreased RAS signaling. The effects were modest, and specificity for transformed cells and efficacy <i>in vivo</i> were not addressed. Nevertheless, this report represents the first step in the development of a promising strategy to overcome the ability of KRAS to evade the therapeutic effects of prenylation inhibitors.</p><p class="" id=d15181e804><b><i>Inhibition of RAS-effector interaction.</i></b> RAS activates its downstream effectors by interaction with their RAS-binding domains (RBDs). Many of the small-molecule RAS direct inhibitors in development appear to work by disrupting these interactions<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a>,<a href="#ref-103">103</a></sup>. Notably, rigosertib, a kinase inhibitor already in phase 3 clinical development for myelodysplastic syndrome, was recently shown to be a RAS mimetic, binding to the RBDs of RAF, PI3K, and RAL-GEF, preventing interaction with RAS and pathway activation<sup><a href="#ref-94">94</a></sup>. Rigosertib was shown to inhibit tumorigenesis in several RAS-driven xenograft models.</p><p class="" id=d15181e824><b><i>Antisense oligonucleotides.</i></b> While therapeutic antisense technology has been hampered by delivery issues, a recent article showed that KRAS expression can be efficiently silenced <i>in vivo</i> by systemic treatment with modified 2',4'-constrained ethyl antisense oligonucleotides<sup><a href="#ref-107">107</a></sup>; toxicity was not seen, and xenograft growth inhibition was demonstrated. If successful in further studies, such an approach may also be applicable to <i>KRAS</i>, <i>HRAS</i>, and <i>RET</i> mutations in MTC.</p></div><div class=section><a name=d15181e847 class=n-a></a><h3 class=section-title>Immunotherapy for medullary thyroid cancer</h3><p class="" id=d15181e852>Exciting recent advances have been made in immunotherapy for a variety of cancers<sup><a href="#ref-114">114</a>–<a href="#ref-118">118</a></sup>. The current state of immunotherapy for thyroid cancer, including MTC, was reviewed recently<sup><a href="#ref-119">119</a></sup>. While effective immunotherapy has not yet reached MTC, there are several points of interest.</p><p class="" id=d15181e866><i>Immune checkpoint therapy</i>. It is not clear whether immune checkpoint therapy has promise in MTC. As noted, MTC has a low mutation burden<sup><a href="#ref-26">26</a></sup>. MTC also has very low expression of the immune checkpoint ligand PD-L1<sup><a href="#ref-120">120</a></sup>; both of these correlate with poor response to checkpoint blockade<sup><a href="#ref-118">118</a>,<a href="#ref-121">121</a>,<a href="#ref-122">122</a></sup>. Nevertheless, in early preclinical and clinical studies, MTC cell or calcitonin vaccines elicited a T-cell response, with apparent antitumor activity<sup><a href="#ref-123">123</a>–<a href="#ref-126">126</a></sup>, suggesting the possibility that checkpoint blockade, perhaps in combination with a vaccine, may be effective. A phase 2 clinical trial (NCT03072160) employing the PD-1 checkpoint-blocking antibody pembrolizumab for MTC will begin to explore this potential therapeutic strategy.</p><p class="" id=d15181e896><i>Adoptive cell therapies: tumor-infiltrating lymphocyte, T-cell receptor, and chimeric antigen receptor transfer</i><sup><a href="#ref-127">127</a>–<a href="#ref-130">130</a></sup>. The low mutation burden of MTC renders these exciting strategies somewhat challenging. Analysis of the most common RET mutations (M918T, C634 mutations) using NetMHC 3.4 software<sup><a href="#ref-131">131</a></sup> failed to identify neoepitopes for avid major histocompatibility complex (MHC) binding in the most common serotypes (unpublished data). Wild-type (and mutated) RET have several epitopes predicted to bind avidly to common MHC alleles; while these could be targeted as potential tumor-associated antigens, the expression of RET in normal cells throughout the body<sup><a href="#ref-132">132</a>,<a href="#ref-133">133</a></sup> raises significant safety concerns of off-tumor toxicity<sup><a href="#ref-134">134</a>,<a href="#ref-135">135</a></sup>.</p><p class="" id=d15181e925>Wang <i>et al</i>. reported recently that peptides surrounding the commonly mutated KRAS G12 position are avidly bound and presented by the HLA-A11*01 serotype<sup><a href="#ref-136">136</a></sup>, facilitating recognition of these KRAS neoepitopes by T-cell receptors. Wang <i>et al</i>. demonstrated that KRAS G12V and KRAS G12D could be recognized by T cells. They isolated high-affinity T-cell receptors specific for these neoepitopes and showed that adoptive transfer of peripheral blood lymphocytes transduced with these KRAS-specific T-cell receptors could effect an antitumor immune response against xenografts harboring the cognate KRAS mutation. While this epitope is not presented by most other common MHC serotypes, Wang <i>et al</i>. note that HLA-A11*01 is present in 14% of the U.S. Caucasian population and in 40% of residents of southern China. Moreover, HRAS and NRAS are identical with KRAS in this region, so this strategy could be effective for all RAS isoforms. A phase 1 clinical trial has been opened for HLA-A11*01-positive patients with tumors harboring a KRAS G12V mutation (NCT03190941); this trial is open to MTC patients.</p><p class="" id=d15181e942><i>Antibody-drug conjugates</i>. MTC and other neuroendocrine tumors commonly express DLL3, a Notch ligand, on their cell surface<sup><a href="#ref-137">137</a>,<a href="#ref-138">138</a></sup>. A DLL3 antibody linked to a DNA crosslinker warhead (Rovalpituzumab tesirine; Rova-T) was shown to efficiently inhibit the growth of DLL3-expressing xenografts; notably, tumor-initiating cells were also targeted. A phase 1 trial of Rova-T in small cell lung cancer showed significant clinical activity, almost exclusively in DLL3-highly expressing tumors<sup><a href="#ref-139">139</a></sup>. A phase 2 trial of Rova-T in DLL3-expressing solid tumors, including a cohort for MTC, is now open (NCT02709889).</p><p class="" id=d15181e958><i>Intracellular antibodies</i>. In general, antibody targeting of intracellular targets has been challenging. However, a recent report describes the construction and preclinical use of a monoclonal antibody that penetrates the cytoplasm and targets activated RAS<sup><a href="#ref-140">140</a></sup>. The antibody was modified to achieve cellular uptake by endocytosis, followed by endosomal escape into the cytosol. By binding activated RAS, the antibody disrupted downstream signaling pathways and interfered with cell growth. While activity <i>in vivo</i> was modest, several strategies were discussed to increase <i>in vivo</i> activity. If successful, this promising, albeit nascent, strategy may be applicable not only for RAS but also for targeting other intracellular targets, including RET M918T in MTC.</p></div><div class=section><a name=d15181e974 class=n-a></a><h3 class=section-title>Peptide receptor radionuclide therapy</h3><p class="" id=d15181e979>Neuroendocrine cancers, including MTC, frequently express somatostatin receptors (SSTRs), and the potential use of somatostatin analogs for imaging, therapy, or therapeutic targeting has been a common focus for many years. In a recently reported phase 3 trial, midgut neuroendocrine tumors were successfully treated by using peptide receptor radionuclide therapy (<i>PRRT</i>)<sup><a href="#ref-141">141</a></sup>. Tumors were stratified by <sup>111</sup>In-DOTATATE scintigraphy for SSTR expression; in SSTR-positive midgut neuroendocrine tumors (NETs), <sup>177</sup>Lu-DOTATATE (Lutathera) treatment resulted in highly significant prolongation of PFS and OS and modestly increased objective response rate (ORR). These results have led to European approval of Lutathera for the treatment of midgut NETs; a new drug application has been submitted to the FDA. Could this PRRT strategy work in MTC? In five small studies in MTC, using either <sup>90</sup>Y- or <sup>177</sup>Lu- somatostatin analogs<sup><a href="#ref-142">142</a>–<a href="#ref-146">146</a></sup> (reviewed in<sup><a href="#ref-147">147</a></sup>), a modest ORR and frequent stable disease were seen. One might envision PRRT as a salvage therapy, stratifying MTC patients with <sup>68</sup>Ga-SST analog positron emission tomography (PET) (<sup>68</sup>Ga-SST analog PET is more sensitive than <sup>111</sup>In-DOTATATE scintigraphy and detects lesions in about 70% of MTC patients with advanced or recurrent disease<sup><a href="#ref-147">147</a>–<a href="#ref-151">151</a></sup>). One concern regarding the potential use of PRRT for MTC is that SSTR expression in MTC has been reported to be focal rather than uniform<sup><a href="#ref-151">151</a>,<a href="#ref-152">152</a></sup>; this tumor heterogeneity could significantly limit efficacy.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15181e1041>Conclusions</h2><p class="" id=d15181e1044>The array of exciting directions for advancing our understanding of MTC, and especially for achieving more effective therapies, has never been more promising. Nevertheless, it must be emphasized that further advances will require careful design of basic, translational, and clinical research. Preclinical resources, including cell lines, animal models, and patient-derived xenografts, are currently very limited. A better understanding of the biology of the C cell and its transformation to MTC is critical. As discussed above, it is imperative to understand the mechanisms of MTC progression on therapy, and this will require extensive analysis of progression biopsies. The recent and future advances in the field validate the tireless and ingenious effort that so many researchers have devoted.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15181e1051>Abbreviations</h2><p class="" id=d15181e1054>EXAM, Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer; FDA, US Food and Drug Administration; FTI, farnesyltransferase inhibitor; GTP, guanosine triphosphate; HR, hazard ratio; IC<sub>50</sub>, concentration resulting in inhibition of 50% of activity; MEN, multiple endocrine neoplasia; MHC, major histocompatibility complex; MTC, medullary thyroid cancer; NET, neuroendocrine tumor; ORR, objective response rate; OS, overall survival; PD, pharmacodynamic; PET, positron emission tomography; PFS, progression-free survival; PK, pharmacokinetic; PRRT, peptide receptor radionuclide therapy; RBD, RAS-binding domain; SST, somatostatin; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor; wt, wild-type.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d15181e1 class=n-a></a><h2 class=main-title id=d15639>Competing interests</h2><p class=metadata-entry><a name=d15181e74 class=n-a></a><p id=d15181e75> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d15181e1 class=n-a></a><h2 class=main-title id=d15641>Grant information</h2><p>The author declares that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d15181e1064 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d16145>References</h2><div class="section ref-list"><a name=d15181e1064 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d15181e1071 class=n-a></a>Wells SA Jr, Pacini F, Robinson BG, <i> et al.</i>: Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. <i>J Clin Endocrinol Metab.</i> 2013; <b>98</b>(8): 3149–64. <a target=xrefwindow id=d15181e1082 href="http://www.ncbi.nlm.nih.gov/pubmed/23744408">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1085 href="http://dx.doi.org/10.1210/jc.2013-1204">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1089 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5399478">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d15181e1098 class=n-a></a>Matias-Guiu X, De Lellis R: Medullary thyroid carcinoma: a 25-year perspective. <i>Endocr Pathol.</i> 2014; <b>25</b>(1): 21–9. <a target=xrefwindow id=d15181e1106 href="http://www.ncbi.nlm.nih.gov/pubmed/24343523">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1109 href="http://dx.doi.org/10.1007/s12022-013-9287-2">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d15181e1118 class=n-a></a>Raue F(Ed.): Medullary thyroid carcinoma. Biology, management, treatment. London: Springer. 2015; 249. <a target=xrefwindow id=d15181e1120 href="http://dx.doi.org/10.1007/978-3-319-22542-5">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d15181e1129 class=n-a></a>Wells SA Jr, Asa SL, Dralle H, <i> et al.</i>: Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. <i>Thyroid.</i> 2015; <b>25</b>(6): 567–610. <a target=xrefwindow id=d15181e1140 href="http://www.ncbi.nlm.nih.gov/pubmed/25810047">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1143 href="http://dx.doi.org/10.1089/thy.2014.0335">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4490627">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d15181e1156 class=n-a></a>Hadoux J, Pacini F, Tuttle RM, <i> et al.</i>: Management of advanced medullary thyroid cancer. <i>Lancet Diabetes Endocrinol.</i> 2016; <b>4</b>(1): 64–71. <a target=xrefwindow id=d15181e1167 href="http://www.ncbi.nlm.nih.gov/pubmed/26608066">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1170 href="http://dx.doi.org/10.1016/S2213-8587(15)00337-X">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d15181e1180 class=n-a></a>Romei C, Ciampi R, Elisei R: A comprehensive overview of the role of the <i>RET</i> proto-oncogene in thyroid carcinoma. <i>Nat Rev Endocrinol.</i> 2016; <b>12</b>(4): 192–202. <a target=xrefwindow id=d15181e1191 href="http://www.ncbi.nlm.nih.gov/pubmed/26868437">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1194 href="http://dx.doi.org/10.1038/nrendo.2016.11">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d15181e1203 class=n-a></a>Wang TS, Evans DB(Eds.): Medullary thyroid cancer. London: Springer. 2016; 197. <a target=xrefwindow id=d15181e1205 href="http://dx.doi.org/10.1007/978-3-319-39412-1">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d15181e1214 class=n-a></a>DeLellis RA, Mangray S: Medullary thyroid carcinoma: a contemporary perspective. <i>AJSP-Reviews and Reports.</i> 2017; <b>22</b>(4): 196–208. <a target=xrefwindow id=d15181e1222 href="http://journals.lww.com/pathologycasereviews/Abstract/2017/07000/Medullary_Thyroid_Carcinoma___A_Contemporary.3.aspx">Reference Source</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d15181e1231 class=n-a></a>Maia AL, Wajner SM, Vargas CV: Advances and controversies in the management of medullary thyroid carcinoma. <i>Curr Opin Oncol.</i> 2017; <b>29</b>(1): 25–32. <a target=xrefwindow id=d15181e1239 href="http://www.ncbi.nlm.nih.gov/pubmed/27792051">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1242 href="http://dx.doi.org/10.1097/CCO.0000000000000340">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d15181e1251 class=n-a></a>Thornton K, Kim G, Maher VE, <i> et al.</i>: Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. <i>Clin Cancer Res.</i> 2012; <b>18</b>(14): 3722–30. <a target=xrefwindow id=d15181e1262 href="http://www.ncbi.nlm.nih.gov/pubmed/22665903">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1265 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-0411">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13359970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1274 class=n-a></a>Wells SA Jr, Robinson BG, Gagel RF, <i> et al.</i>: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. <i>J Clin Oncol.</i> 2012; <b>30</b>(2): 134–41. <a target=xrefwindow id=d15181e1285 href="http://www.ncbi.nlm.nih.gov/pubmed/22025146">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1288 href="http://dx.doi.org/10.1200/JCO.2011.35.5040">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1292 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3675689">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13359970">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718098672"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1306 class=n-a></a>Elisei R, Schlumberger MJ, Müller SP, <i> et al.</i>: Cabozantinib in progressive medullary thyroid cancer. <i>J Clin Oncol.</i> 2013; <b>31</b>(29): 3639–46. <a target=xrefwindow id=d15181e1317 href="http://www.ncbi.nlm.nih.gov/pubmed/24002501">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1320 href="http://dx.doi.org/10.1200/JCO.2012.48.4659">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1324 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4164813">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718098672">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d15181e1337 class=n-a></a>Le Douarin N, Le Lièvre C: [Demonstration of neural origin of calcitonin cells of ultimobranchial body of chick embryo]. <i>C R Acad Sci Hebd Seances Acad Sci D.</i> 1970; <b>270</b>(23): 2857–60. <a target=xrefwindow id=d15181e1345 href="http://www.ncbi.nlm.nih.gov/pubmed/4987935">PubMed Abstract </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d15181e1354 class=n-a></a>Polak JM, Pearse AG, Le Lièvre C, <i> et al.</i>: Immunocytochemical confirmation of the neural crest origin of avian calcitonin-producing cells. <i>Histochemistry.</i> 1974; <b>40</b>(3): 209–14. <a target=xrefwindow id=d15181e1365 href="http://www.ncbi.nlm.nih.gov/pubmed/4604566">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1368 href="http://dx.doi.org/10.1007/BF00501955">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d15181e1377 class=n-a></a>Kameda Y, Nishimaki T, Miura M, <i> et al.</i>: <i>Mash1</i> regulates the development of C cells in mouse thyroid glands. <i>Dev Dyn.</i> 2007; <b>236</b>(1): 262–70. <a target=xrefwindow id=d15181e1391 href="http://www.ncbi.nlm.nih.gov/pubmed/17103415">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1395 href="http://dx.doi.org/10.1002/dvdy.21018">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725803620"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1404 class=n-a></a>Johansson E, Andersson L, Örnros J, <i> et al.</i>: Revising the embryonic origin of thyroid C cells in mice and humans. <i>Development.</i> 2015; <b>142</b>(20): 3519–28. <a target=xrefwindow id=d15181e1415 href="http://www.ncbi.nlm.nih.gov/pubmed/26395490">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1418 href="http://dx.doi.org/10.1242/dev.126581">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1422 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4631767">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725803620">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d15181e1435 class=n-a></a>Kameda Y: Cellular and molecular events on the development of mammalian thyroid C cells. <i>Dev Dyn.</i> 2016; <b>245</b>(3): 323–41. <a target=xrefwindow id=d15181e1443 href="http://www.ncbi.nlm.nih.gov/pubmed/26661795">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1446 href="http://dx.doi.org/10.1002/dvdy.24377">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725398613"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1456 class=n-a></a>Bagheri-Yarmand R, Sinha KM, Gururaj AE, <i> et al.</i>: A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis. <i>J Biol Chem.</i> 2015; <b>290</b>(18): 11749–61. <a target=xrefwindow id=d15181e1467 href="http://www.ncbi.nlm.nih.gov/pubmed/25795775">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1470 href="http://dx.doi.org/10.1074/jbc.M114.619833">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1474 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4416875">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725398613">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d15181e1487 class=n-a></a>Drosten M, Hilken G, Böckmann M, <i> et al.</i>: Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. <i>J Natl Cancer Inst.</i> 2004; <b>96</b>(16): 1231–9. <a target=xrefwindow id=d15181e1498 href="http://www.ncbi.nlm.nih.gov/pubmed/15316058">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1501 href="http://dx.doi.org/10.1093/jnci/djh226">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727141360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1510 class=n-a></a>Plaza-Menacho I, Barnouin K, Barry R, <i> et al.</i>: RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements. <i>Cell Rep.</i> 2016; <b>17</b>(12): 3319–32. <a target=xrefwindow id=d15181e1521 href="http://www.ncbi.nlm.nih.gov/pubmed/28009299">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1524 href="http://dx.doi.org/10.1016/j.celrep.2016.11.061">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1528 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5199340">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727141360">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d15181e1541 class=n-a></a>Read RD, Goodfellow PJ, Mardis ER, <i> et al.</i>: A Drosophila model of multiple endocrine neoplasia type 2. <i>Genetics.</i> 2005; <b>171</b>(3): 1057–81. <a target=xrefwindow id=d15181e1552 href="http://www.ncbi.nlm.nih.gov/pubmed/15965261">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1555 href="http://dx.doi.org/10.1534/genetics.104.038018">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1559 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1456812">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d15181e1568 class=n-a></a>Cote GJ, Grubbs EG, Hofmann MC: Thyroid C-cell biology and oncogenic transformation. <i>Recent Results Cancer Res.</i> 2015; <b>204</b>: 1–39. <a target=xrefwindow id=d15181e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/26494382">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1579 href="http://dx.doi.org/10.1007/978-3-319-22542-5_1">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5640981">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d15181e1591 class=n-a></a>Barasch JM, Mackey H, Tamir H, <i> et al.</i>: Induction of a neural phenotype in a serotonergic endocrine cell derived from the neural crest. <i>J Neurosci.</i> 1987; <b>7</b>(9): 2874–83. <a target=xrefwindow id=d15181e1602 href="http://www.ncbi.nlm.nih.gov/pubmed/3305802">PubMed Abstract </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d15181e1612 class=n-a></a>Moerch U, Nielsen HS, Lundsgaard D, <i> et al.</i>: Flow sorting from organ material by intracellular markers. <i>Cytometry A.</i> 2007; <b>71</b>(7): 495–500. <a target=xrefwindow id=d15181e1623 href="http://www.ncbi.nlm.nih.gov/pubmed/17542026">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1626 href="http://dx.doi.org/10.1002/cyto.a.20418">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d15181e1635 class=n-a></a>Gawade S, Mayer C, Hafen K, <i> et al.</i>: Cell growth dynamics in embryonic and adult mouse thyroid revealed by a novel approach to detect thyroid gland subpopulations. <i>Thyroid.</i> 2016; <b>26</b>(4): 591–9. <a target=xrefwindow id=d15181e1646 href="http://www.ncbi.nlm.nih.gov/pubmed/26854713">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1649 href="http://dx.doi.org/10.1089/thy.2015.0523">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717969054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1658 class=n-a></a>Agrawal N, Jiao Y, Sausen M, <i> et al.</i>: Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in <i>RET</i> and <i>RAS</i>. <i>J Clin Endocrinol Metab.</i> 2013; <b>98</b>(2): E364–9. <a target=xrefwindow id=d15181e1676 href="http://www.ncbi.nlm.nih.gov/pubmed/23264394">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1679 href="http://dx.doi.org/10.1210/jc.2012-2703">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1682 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3565108">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717969054">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8960956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1695 class=n-a></a>Moura MM, Cavaco BM, Pinto AE, <i> et al.</i>: High prevalence of <i>RAS</i> mutations in <i>RET</i>-negative sporadic medullary thyroid carcinomas. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(5): E863–8. <a target=xrefwindow id=d15181e1713 href="http://www.ncbi.nlm.nih.gov/pubmed/21325462">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1716 href="http://dx.doi.org/10.1210/jc.2010-1921">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8960956">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d15181e1729 class=n-a></a>Schulten H, Al-Maghrabi J, Al-Ghamdi K, <i> et al.</i>: Mutational screening of <i>RET, HRAS, KRAS, NRAS, BRAF, AKT1</i>, and <i>CTNNB1</i> in medullary thyroid carcinoma. <i>Anticancer Res.</i> 2011; <b>31</b>(12): 4179–83. <a target=xrefwindow id=d15181e1747 href="http://www.ncbi.nlm.nih.gov/pubmed/22199277">PubMed Abstract </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d15181e1756 class=n-a></a>Boichard A, Croux L, Al Ghuzlan A, <i> et al.</i>: Somatic <i>RAS</i> mutations occur in a large proportion of sporadic <i>RET</i>-negative medullary thyroid carcinomas and extend to a previously unidentified exon. <i>J Clin Endocrinol Metab.</i> 2012; <b>97</b>(10): E2031–5. <a target=xrefwindow id=d15181e1774 href="http://www.ncbi.nlm.nih.gov/pubmed/22865907">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1777 href="http://dx.doi.org/10.1210/jc.2012-2092">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1780 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3462939">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717969682"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1790 class=n-a></a>Ciampi R, Mian C, Fugazzola L, <i> et al.</i>: Evidence of a low prevalence of <i>RAS</i> mutations in a large medullary thyroid cancer series. <i>Thyroid.</i> 2013; <b>23</b>(1): 50–7. <a target=xrefwindow id=d15181e1804 href="http://www.ncbi.nlm.nih.gov/pubmed/23240926">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1808 href="http://dx.doi.org/10.1089/thy.2012.0207">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717969682">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d15181e1821 class=n-a></a>Moura MM, Cavaco BM, Leite V: <i>RAS</i> proto-oncogene in medullary thyroid carcinoma. <i>Endocr Relat Cancer.</i> 2015; <b>22</b>(5): R235–52. <a target=xrefwindow id=d15181e1832 href="http://www.ncbi.nlm.nih.gov/pubmed/26285815">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1835 href="http://dx.doi.org/10.1530/ERC-15-0070">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725289666"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1844 class=n-a></a>Grubbs EG, Ng PK, Bui J, <i> et al.</i>: RET fusion as a novel driver of medullary thyroid carcinoma. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(3): 788–93. <a target=xrefwindow id=d15181e1855 href="http://www.ncbi.nlm.nih.gov/pubmed/25546157">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1858 href="http://dx.doi.org/10.1210/jc.2014-4153">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1862 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4333032">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725289666">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725732110"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1875 class=n-a></a>Ji JH, Oh YL, Hong M, <i> et al.</i>: Identification of driving <i>ALK</i> fusion genes and genomic landscape of medullary thyroid cancer. <i>PLoS Genet.</i> 2015; <b>11</b>(8): e1005467. <a target=xrefwindow id=d15181e1889 href="http://www.ncbi.nlm.nih.gov/pubmed/26295973">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1893 href="http://dx.doi.org/10.1371/journal.pgen.1005467">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4546689">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725732110">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1119"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e1909 class=n-a></a>Tomlins SA, Rhodes DR, Perner S, <i> et al.</i>: Recurrent fusion of <i>TMPRSS2</i> and ETS transcription factor genes in prostate cancer. <i>Science.</i> 2005; <b>310</b>(5748): 644–8. <a target=xrefwindow id=d15181e1923 href="http://www.ncbi.nlm.nih.gov/pubmed/16254181">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1927 href="http://dx.doi.org/10.1126/science.1117679">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1119">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d15181e1940 class=n-a></a>Rubin MA, Maher CA, Chinnaiyan AM: Common gene rearrangements in prostate cancer. <i>J Clin Oncol.</i> 2011; <b>29</b>(27): 3659–68. <a target=xrefwindow id=d15181e1948 href="http://www.ncbi.nlm.nih.gov/pubmed/21859993">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1951 href="http://dx.doi.org/10.1200/JCO.2011.35.1916">Publisher Full Text </a> | <a target=xrefwindow id=d15181e1954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4874145">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d15181e1964 class=n-a></a>Mertens F, Johansson B, Fioretos T, <i> et al.</i>: The emerging complexity of gene fusions in cancer. <i>Nat Rev Cancer.</i> 2015; <b>15</b>(6): 371–81. <a target=xrefwindow id=d15181e1975 href="http://www.ncbi.nlm.nih.gov/pubmed/25998716">PubMed Abstract </a> | <a target=xrefwindow id=d15181e1978 href="http://dx.doi.org/10.1038/nrc3947">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d15181e1987 class=n-a></a>Gottesman MM, Lavi O, Hall MD, <i> et al.</i>: Toward a better understanding of the complexity of cancer drug resistance. <i>Annu Rev Pharmacol Toxicol.</i> 2016; <b>56</b>: 85–102. <a target=xrefwindow id=d15181e1998 href="http://www.ncbi.nlm.nih.gov/pubmed/26514196">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2001 href="http://dx.doi.org/10.1146/annurev-pharmtox-010715-103111">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717967828"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2010 class=n-a></a>Diaz LA Jr, Williams RT, Wu J, <i> et al.</i>: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. <i>Nature.</i> 2012; <b>486</b>(7404): 537–40. <a target=xrefwindow id=d15181e2021 href="http://www.ncbi.nlm.nih.gov/pubmed/22722843">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2024 href="http://dx.doi.org/10.1038/nature11219">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3436069">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717967828">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d15181e2041 class=n-a></a>Bozic I, Gerold JM, Nowak MA: Quantifying clonal and subclonal passenger mutations in cancer evolution. <i>PLoS Comput Biol.</i> 2016; <b>12</b>(2): e1004731. <a target=xrefwindow id=d15181e2049 href="http://www.ncbi.nlm.nih.gov/pubmed/26828429">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2052 href="http://dx.doi.org/10.1371/journal.pcbi.1004731">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4734774">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727288292"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2064 class=n-a></a>McGranahan N, Swanton C: Clonal heterogeneity and tumor evolution: past, present, and the future. <i>Cell.</i> 2017; <b>168</b>(4): 613–28. <a target=xrefwindow id=d15181e2072 href="http://www.ncbi.nlm.nih.gov/pubmed/28187284">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2075 href="http://dx.doi.org/10.1016/j.cell.2017.01.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727288292">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d15181e2088 class=n-a></a>Kantarjian H, Giles F, Wunderle L, <i> et al.</i>: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. <i>N Engl J Med.</i> 2006; <b>354</b>(24): 2542–51. <a target=xrefwindow id=d15181e2099 href="http://www.ncbi.nlm.nih.gov/pubmed/16775235">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2102 href="http://dx.doi.org/10.1056/NEJMoa055104">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11812958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2112 class=n-a></a>de Bono JS, Logothetis CJ, Molina A, <i> et al.</i>: Abiraterone and increased survival in metastatic prostate cancer. <i>N Engl J Med.</i> 2011; <b>364</b>(21): 1995–2005. <a target=xrefwindow id=d15181e2123 href="http://www.ncbi.nlm.nih.gov/pubmed/21612468">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2126 href="http://dx.doi.org/10.1056/NEJMoa1014618">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2130 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3471149">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11812958">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717958121"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2143 class=n-a></a>Flaherty KT, Infante JR, Daud A, <i> et al.</i>: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>N Engl J Med.</i> 2012; <b>367</b>(18): 1694–703. <a target=xrefwindow id=d15181e2154 href="http://www.ncbi.nlm.nih.gov/pubmed/23020132">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2157 href="http://dx.doi.org/10.1056/NEJMoa1210093">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2161 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3549295">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717958121">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717953862"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2174 class=n-a></a>Scher HI, Fizazi K, Saad F, <i> et al.</i>: Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>N Engl J Med.</i> 2012; <b>367</b>(13): 1187–97. <a target=xrefwindow id=d15181e2185 href="http://www.ncbi.nlm.nih.gov/pubmed/22894553">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2188 href="http://dx.doi.org/10.1056/NEJMoa1207506">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717953862">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d15181e2201 class=n-a></a>Zhang C, Spevak W, Zhang Y, <i> et al.</i>: RAF inhibitors that evade paradoxical MAPK pathway activation. <i>Nature.</i> 2015; <b>526</b>(7574): 583–6. <a target=xrefwindow id=d15181e2212 href="http://www.ncbi.nlm.nih.gov/pubmed/26466569">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2215 href="http://dx.doi.org/10.1038/nature14982">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d15181e2224 class=n-a></a>Mok TS, Wu YL, Ahn MJ, <i> et al.</i>: Osimertinib or platinum-pemetrexed in <i>EGFR</i> T790M-positive lung cancer. <i>N Engl J Med.</i> 2017; <b>376</b>(7): 629–40. <a target=xrefwindow id=d15181e2238 href="http://www.ncbi.nlm.nih.gov/pubmed/27959700">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2242 href="http://dx.doi.org/10.1056/NEJMoa1612674">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d15181e2251 class=n-a></a>Carlomagno F, Guida T, Anaganti S, <i> et al.</i>: Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. <i>Oncogene.</i> 2004; <b>23</b>(36): 6056–63. <a target=xrefwindow id=d15181e2262 href="http://www.ncbi.nlm.nih.gov/pubmed/15184865">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2265 href="http://dx.doi.org/10.1038/sj.onc.1207810">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d15181e2275 class=n-a></a>Mologni L, Redaelli S, Morandi A, <i> et al.</i>: Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. <i>Mol Cell Endocrinol.</i> 2013; <b>377</b>(1–2): 1–6. <a target=xrefwindow id=d15181e2286 href="http://www.ncbi.nlm.nih.gov/pubmed/23811235">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2289 href="http://dx.doi.org/10.1016/j.mce.2013.06.025">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d15181e2298 class=n-a></a>Shah NP, Nicoll JM, Nagar B, <i> et al.</i>: Multiple <i>BCR-ABL</i> kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. <i>Cancer Cell.</i> 2002; <b>2</b>(2): 117–25. <a target=xrefwindow id=d15181e2312 href="http://www.ncbi.nlm.nih.gov/pubmed/12204532">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2316 href="http://dx.doi.org/10.1016/S1535-6108(02)00096-X">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d15181e2325 class=n-a></a>Plenker D, Riedel M, Brägelmann J, <i> et al.</i>: Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Sci Transl Med.</i> 2017; <b>9</b>(394): pii: eaah6144. <a target=xrefwindow id=d15181e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/28615362">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2339 href="http://dx.doi.org/10.1126/scitranslmed.aah6144">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d15181e2348 class=n-a></a>Roberts KG, Odell AF, Byrnes EM, <i> et al.</i>: Resistance to c-KIT kinase inhibitors conferred by V654A mutation. <i>Mol Cancer Ther.</i> 2007; <b>6</b>(3): 1159–66. <a target=xrefwindow id=d15181e2359 href="http://www.ncbi.nlm.nih.gov/pubmed/17363509">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2362 href="http://dx.doi.org/10.1158/1535-7163.MCT-06-0641">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d15181e2371 class=n-a></a>Weil A, Martin P, Smith R, <i> et al.</i>: Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. <i>Clin Pharmacokinet.</i> 2010; <b>49</b>(9): 607–18. <a target=xrefwindow id=d15181e2382 href="http://www.ncbi.nlm.nih.gov/pubmed/20690783">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2385 href="http://dx.doi.org/10.2165/11534330-000000000-00000">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d15181e2394 class=n-a></a>U.S. Food and Drug Administration: Clinical pharmacology and biometrics review(s). Silver Spring (MD): U.S. Food and Drug Administration; 2012. <a target=xrefwindow id=d15181e2396 href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203756Orig1s000PharmR.pdf">Reference Source</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d15181e2406 class=n-a></a>Singh H, Brave M, Beaver JA, <i> et al.</i>: U.S. Food and Drug Administration approval: cabozantinib for the treatment of advanced renal cell carcinoma. <i>Clin Cancer Res.</i> 2017; <b>23</b>(2): 330–5. <a target=xrefwindow id=d15181e2417 href="http://www.ncbi.nlm.nih.gov/pubmed/27793960">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2420 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-1073">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726637679"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2429 class=n-a></a>Sherman SI, Clary DO, Elisei R, <i> et al.</i>: Correlative analyses of <i>RET</i> and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. <i>Cancer.</i> 2016; <b>122</b>(24): 3856–64. <a target=xrefwindow id=d15181e2443 href="http://www.ncbi.nlm.nih.gov/pubmed/27525386">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2447 href="http://dx.doi.org/10.1002/cncr.30252">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726637679">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d15181e2460 class=n-a></a>Schlumberger M, Elisei R, Müller S, <i> et al.</i>: Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Ann Oncol.</i> 2017; <b>28</b>(11): 2813–2819. <a target=xrefwindow id=d15181e2471 href="http://www.ncbi.nlm.nih.gov/pubmed/29045520">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2474 href="http://dx.doi.org/10.1093/annonc/mdx479">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1021472"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2483 class=n-a></a>Jain S, Watson MA, DeBenedetti MK, <i> et al.</i>: Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. <i>Cancer Res.</i> 2004; <b>64</b>(11): 3907–13. <a target=xrefwindow id=d15181e2494 href="http://www.ncbi.nlm.nih.gov/pubmed/15173001">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2497 href="http://dx.doi.org/10.1158/0008-5472.CAN-03-3801">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1021472">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d15181e2510 class=n-a></a>Ameur N, Lacroix L, Roucan S, <i> et al.</i>: Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. <i>Endocr Relat Cancer.</i> 2009; <b>16</b>(4): 1261–72. <a target=xrefwindow id=d15181e2521 href="http://www.ncbi.nlm.nih.gov/pubmed/19675075">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2524 href="http://dx.doi.org/10.1677/ERC-08-0289">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717967672"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2533 class=n-a></a>Maliszewska A, Leandro-Garcia LJ, Castelblanco E, <i> et al.</i>: Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. <i>Am J Pathol.</i> 2013; <b>182</b>(2): 350–62. <a target=xrefwindow id=d15181e2544 href="http://www.ncbi.nlm.nih.gov/pubmed/23201134">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2547 href="http://dx.doi.org/10.1016/j.ajpath.2012.10.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717967672">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d15181e2561 class=n-a></a>Oczko-Wojciechowska M, Swierniak M, Krajewska J, <i> et al.</i>: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of <i>RET</i> gene mutations. <i>Sci Rep.</i> 2017; <b>7</b>: 42074. <a target=xrefwindow id=d15181e2575 href="http://www.ncbi.nlm.nih.gov/pubmed/28181547">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2579 href="http://dx.doi.org/10.1038/srep42074">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5299608">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d15181e2591 class=n-a></a>Songyang Z, Carraway KL 3rd, Eck MJ, <i> et al.</i>: Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. <i>Nature.</i> 1995; <b>373</b>(6514): 536–9. <a target=xrefwindow id=d15181e2602 href="http://www.ncbi.nlm.nih.gov/pubmed/7845468">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2605 href="http://dx.doi.org/10.1038/373536a0">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d15181e2614 class=n-a></a>Gujral TS, Singh VK, Jia Z, <i> et al.</i>: Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. <i>Cancer Res.</i> 2006; <b>66</b>(22): 10741–9. <a target=xrefwindow id=d15181e2625 href="http://www.ncbi.nlm.nih.gov/pubmed/17108110">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2628 href="http://dx.doi.org/10.1158/0008-5472.CAN-06-3329">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d15181e2637 class=n-a></a>Dixit A, Torkamani A, Schork NJ, <i> et al.</i>: Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. <i>Biophys J.</i> 2009; <b>96</b>(3): 858–74. <a target=xrefwindow id=d15181e2648 href="http://www.ncbi.nlm.nih.gov/pubmed/19186126">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2651 href="http://dx.doi.org/10.1016/j.bpj.2008.10.041">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2716637">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d15181e2664 class=n-a></a>George Priya Doss C, Rajith B, Chakraboty C, <i> et al.</i>: <i>In silico</i> profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach. <i>Mol Biosyst.</i> 2014; <b>10</b>(3): 421–36. <a target=xrefwindow id=d15181e2678 href="http://www.ncbi.nlm.nih.gov/pubmed/24336963">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2682 href="http://dx.doi.org/10.1039/c3mb70427k">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d15181e2691 class=n-a></a>Yakes FM, Chen J, Tan J, <i> et al.</i>: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. <i>Mol Cancer Ther.</i> 2011; <b>10</b>(12): 2298–308. <a target=xrefwindow id=d15181e2702 href="http://www.ncbi.nlm.nih.gov/pubmed/21926191">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2705 href="http://dx.doi.org/10.1158/1535-7163.MCT-11-0264">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d15181e2715 class=n-a></a>Fujita-Sato S, Galeas J, Truitt M, <i> et al.</i>: Enhanced MET translation and signaling sustains K-Ras-driven proliferation under anchorage-independent growth conditions. <i>Cancer Res.</i> 2015; <b>75</b>(14): 2851–62. <a target=xrefwindow id=d15181e2726 href="http://www.ncbi.nlm.nih.gov/pubmed/25977330">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2729 href="http://dx.doi.org/10.1158/0008-5472.CAN-14-1623">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2733 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4506276">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d15181e2742 class=n-a></a>Mologni L, Gambacorti-Passerini C, Goekjian P, <i> et al.</i>: RET kinase inhibitors: a review of recent patents (2012–2015). <i>Expert Opin Ther Pat.</i> 2017; <b>27</b>(1): 91–9. <a target=xrefwindow id=d15181e2753 href="http://www.ncbi.nlm.nih.gov/pubmed/27646564">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2756 href="http://dx.doi.org/10.1080/13543776.2017.1238073">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d15181e2765 class=n-a></a>Kodama T, Tsukaguchi T, Satoh Y, <i> et al.</i>: Alectinib shows potent antitumor activity against <i>RET</i>-rearranged non-small cell lung cancer. <i>Mol Cancer Ther.</i> 2014; <b>13</b>(12): 2910–8. <a target=xrefwindow id=d15181e2779 href="http://www.ncbi.nlm.nih.gov/pubmed/25349307">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2783 href="http://dx.doi.org/10.1158/1535-7163.MCT-14-0274">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d15181e2792 class=n-a></a>Rahal R, Evans EK, Hu W, <i> et al.</i>: Abstract 2641: the development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors. <i>Cancer Res.</i> 2016; <b>76</b>(14): 2641. <a target=xrefwindow id=d15181e2803 href="http://dx.doi.org/10.1158/1538-7445.AM2016-2641">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d15181e2812 class=n-a></a>Brandhuber B, Haas J, Tuch B, <i> et al.</i>: The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. <i>Eur J Cancer.</i> 2016; <b>69</b>(Supplement 1): S144. <a target=xrefwindow id=d15181e2823 href="http://dx.doi.org/10.1016/S0959-8049(16)33028-3">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d15181e2832 class=n-a></a>James J, Ruggeri B, Armstrong RC, <i> et al.</i>: CEP-32496: a novel orally active BRAF<sup>V600E</sup> inhibitor with selective cellular and <i>in vivo</i> antitumor activity. <i>Mol Cancer Ther.</i> 2012; <b>11</b>(4): 930–41. <a target=xrefwindow id=d15181e2850 href="http://www.ncbi.nlm.nih.gov/pubmed/22319199">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2853 href="http://dx.doi.org/10.1158/1535-7163.MCT-11-0645">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d15181e2863 class=n-a></a>Koh YW, Shah MH, Agarwal K, <i> et al.</i>: Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma <i>in vitro</i>. <i>Endocr Relat Cancer.</i> 2012; <b>19</b>(1): 29–38. <a target=xrefwindow id=d15181e2877 href="http://www.ncbi.nlm.nih.gov/pubmed/22109971">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2881 href="http://dx.doi.org/10.1530/ERC-11-0155">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2884 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3717592">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2353965"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2893 class=n-a></a>Hatzivassiliou G, Song K, Yen I, <i> et al.</i>: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. <i>Nature.</i> 2010; <b>464</b>(7287): 431–5. <a target=xrefwindow id=d15181e2904 href="http://www.ncbi.nlm.nih.gov/pubmed/20130576">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2907 href="http://dx.doi.org/10.1038/nature08833">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2353965">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1818967"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2920 class=n-a></a>Heidorn SJ, Milagre C, Whittaker S, <i> et al.</i>: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. <i>Cell.</i> 2010; <b>140</b>(2): 209–21. <a target=xrefwindow id=d15181e2931 href="http://www.ncbi.nlm.nih.gov/pubmed/20141835">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2934 href="http://dx.doi.org/10.1016/j.cell.2009.12.040">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2872605">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1818967">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2353964"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e2951 class=n-a></a>Poulikakos PI, Zhang C, Bollag G, <i> et al.</i>: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. <i>Nature.</i> 2010; <b>464</b>(7287): 427–30. <a target=xrefwindow id=d15181e2962 href="http://www.ncbi.nlm.nih.gov/pubmed/20179705">PubMed Abstract </a> | <a target=xrefwindow id=d15181e2965 href="http://dx.doi.org/10.1038/nature08902">Publisher Full Text </a> | <a target=xrefwindow id=d15181e2969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3178447">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2353964">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d15181e2982 class=n-a></a>Li GG, Somwar R, Joseph J, <i> et al.</i>: Antitumor activity of RXDX-105 in multiple cancer types with <i>RET</i> rearrangements or mutations. <i>Clin Cancer Res.</i> 2017; <b>23</b>(12): 2981–90. <a target=xrefwindow id=d15181e2996 href="http://www.ncbi.nlm.nih.gov/pubmed/28011461">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3000 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-1887">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3003 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5477238">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d15181e3012 class=n-a></a>Ohiwa M, Murakami H, Iwashita T, <i> et al.</i>: Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations. <i>Biochem Biophys Res Commun.</i> 1997; <b>237</b>(3): 747–51. <a target=xrefwindow id=d15181e3023 href="http://www.ncbi.nlm.nih.gov/pubmed/9299438">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3026 href="http://dx.doi.org/10.1006/bbrc.1997.7225">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d15181e3036 class=n-a></a>Cox AD, Fesik SW, Kimmelman AC, <i> et al.</i>: Drugging the undruggable RAS: mission possible? <i>Nat Rev Drug Discov.</i> 2014; <b>13</b>(11): 828–51. <a target=xrefwindow id=d15181e3047 href="http://www.ncbi.nlm.nih.gov/pubmed/25323927">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3050 href="http://dx.doi.org/10.1038/nrd4389">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4355017">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d15181e3063 class=n-a></a>Stephen AG, Esposito D, Bagni RK, <i> et al.</i>: Dragging ras back in the ring. <i>Cancer Cell.</i> 2014; <b>25</b>(3): 272–81. <a target=xrefwindow id=d15181e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/24651010">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3077 href="http://dx.doi.org/10.1016/j.ccr.2014.02.017">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d15181e3086 class=n-a></a>Papke B, Der CJ: Drugging RAS: know the enemy. <i>Science.</i> 2017; <b>355</b>(6330): 1158–63. <a target=xrefwindow id=d15181e3094 href="http://www.ncbi.nlm.nih.gov/pubmed/28302824">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3097 href="http://dx.doi.org/10.1126/science.aam7622">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d15181e3106 class=n-a></a>Goody RS, Frech M, Wittinghofer A: Affinity of guanine nucleotide binding proteins for their ligands: facts and artefacts. <i>Trends Biochem Sci.</i> 1991; <b>16</b>(9): 327–8. <a target=xrefwindow id=d15181e3114 href="http://www.ncbi.nlm.nih.gov/pubmed/1949151">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3117 href="http://dx.doi.org/10.1016/0968-0004(91)90134-H">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d15181e3126 class=n-a></a>James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic <i>in vitro</i>. <i>J Biol Chem.</i> 1995; <b>270</b>(11): 6221–6. <a target=xrefwindow id=d15181e3137 href="http://www.ncbi.nlm.nih.gov/pubmed/7890759">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3140 href="http://dx.doi.org/10.1074/jbc.270.11.6221">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d15181e3149 class=n-a></a>Rowell CA, Kowalczyk JJ, Lewis MD, <i> et al.</i>: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras <i>in vivo</i>. <i>J Biol Chem.</i> 1997; <b>272</b>(22): 14093–7. <a target=xrefwindow id=d15181e3163 href="http://www.ncbi.nlm.nih.gov/pubmed/9162034">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3167 href="http://dx.doi.org/10.1074/jbc.272.22.14093">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d15181e3177 class=n-a></a>Whyte DB, Kirschmeier P, Hockenberry TN, <i> et al.</i>: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. <i>J Biol Chem.</i> 1997; <b>272</b>(22): 14459–64. <a target=xrefwindow id=d15181e3188 href="http://www.ncbi.nlm.nih.gov/pubmed/9162087">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3191 href="http://dx.doi.org/10.1074/jbc.272.22.14459">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d15181e3200 class=n-a></a>Grilley-Olson JE, Bedard PL, Fasolo A, <i> et al.</i>: A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. <i>Invest New Drugs.</i> 2016; <b>34</b>(6): 740–9. <a target=xrefwindow id=d15181e3211 href="http://www.ncbi.nlm.nih.gov/pubmed/27450049">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3214 href="http://dx.doi.org/10.1007/s10637-016-0377-0">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14233956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3223 class=n-a></a>Maurer T, Garrenton LS, Oh A, <i> et al.</i>: Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. <i>Proc Natl Acad Sci U S A.</i> 2012; <b>109</b>(14): 5299–304. <a target=xrefwindow id=d15181e3234 href="http://www.ncbi.nlm.nih.gov/pubmed/22431598">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3237 href="http://dx.doi.org/10.1073/pnas.1116510109">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3241 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3325706">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14233956">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718182175"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3254 class=n-a></a>Ostrem JM, Peters U, Sos ML, <i> et al.</i>: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. <i>Nature.</i> 2013; <b>503</b>(7477): 548–51. <a target=xrefwindow id=d15181e3265 href="http://www.ncbi.nlm.nih.gov/pubmed/24256730">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3268 href="http://dx.doi.org/10.1038/nature12796">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3272 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4274051">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718182175">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718012755"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3285 class=n-a></a>Zimmermann G, Papke B, Ismail S, <i> et al.</i>: Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. <i>Nature.</i> 2013; <b>497</b>(7451): 638–42. <a target=xrefwindow id=d15181e3296 href="http://www.ncbi.nlm.nih.gov/pubmed/23698361">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3299 href="http://dx.doi.org/10.1038/nature12205">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718012755">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d15181e3312 class=n-a></a>Zorde Khvalevsky E, Gabai R, Rachmut IH, <i> et al.</i>: Mutant KRAS is a druggable target for pancreatic cancer. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(51): 20723–8. <a target=xrefwindow id=d15181e3323 href="http://www.ncbi.nlm.nih.gov/pubmed/24297898">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3326 href="http://dx.doi.org/10.1073/pnas.1314307110">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3870687">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d15181e3340 class=n-a></a>Burns MC, Sun Q, Daniels RN, <i> et al.</i>: Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(9): 3401–6. <a target=xrefwindow id=d15181e3351 href="http://www.ncbi.nlm.nih.gov/pubmed/24550516">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3354 href="http://dx.doi.org/10.1073/pnas.1315798111">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3358 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3948241">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d15181e3367 class=n-a></a>Hunter JC, Gurbani D, Ficarro SB, <i> et al.</i>: <i>In situ</i> selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(24): 8895–900. <a target=xrefwindow id=d15181e3381 href="http://www.ncbi.nlm.nih.gov/pubmed/24889603">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3385 href="http://dx.doi.org/10.1073/pnas.1404639111">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4066474">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718183852"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3397 class=n-a></a>Lim SM, Westover KD, Ficarro SB, <i> et al.</i>: Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. <i>Angew Chem Int Ed Engl.</i> 2014; <b>53</b>(1): 199–204. <a target=xrefwindow id=d15181e3408 href="http://www.ncbi.nlm.nih.gov/pubmed/24259466">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3411 href="http://dx.doi.org/10.1002/anie.201307387">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3415 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3914205">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718183852">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725478250"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3428 class=n-a></a>Upadhyaya P, Qian Z, Selner NG, <i> et al.</i>: Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. <i>Angew Chem Int Ed Engl.</i> 2015; <b>54</b>(26): 7602–6. <a target=xrefwindow id=d15181e3439 href="http://www.ncbi.nlm.nih.gov/pubmed/25950772">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3442 href="http://dx.doi.org/10.1002/anie.201502763">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3446 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4591930">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725478250">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726306223"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3459 class=n-a></a>Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, <i> et al.</i>: A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. <i>Cell.</i> 2016; <b>165</b>(3): 643–55. <a target=xrefwindow id=d15181e3470 href="http://www.ncbi.nlm.nih.gov/pubmed/27104980">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3473 href="http://dx.doi.org/10.1016/j.cell.2016.03.045">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3477 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5006944">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726306223">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726073659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3490 class=n-a></a>Lito P, Solomon M, Li LS, <i> et al.</i>: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. <i>Science.</i> 2016; <b>351</b>(6273): 604–8. <a target=xrefwindow id=d15181e3501 href="http://www.ncbi.nlm.nih.gov/pubmed/26841430">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3504 href="http://dx.doi.org/10.1126/science.aad6204">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3508 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4955282">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726073659">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d15181e3522 class=n-a></a>Lu S, Jang H, Gu S, <i> et al.</i>: Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. <i>Chem Soc Rev.</i> 2016; <b>45</b>(18): 4929–52. <a target=xrefwindow id=d15181e3533 href="http://www.ncbi.nlm.nih.gov/pubmed/27396271">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3536 href="http://dx.doi.org/10.1039/c5cs00911a">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3540 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5021603">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d15181e3549 class=n-a></a>McCormick F: K-Ras protein as a drug target. <i>J Mol Med (Berl).</i> 2016; <b>94</b>(3): 253–8. <a target=xrefwindow id=d15181e3557 href="http://www.ncbi.nlm.nih.gov/pubmed/26960760">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3560 href="http://dx.doi.org/10.1007/s00109-016-1382-7">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4803814">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726585199"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3572 class=n-a></a>Ostrem JM, Shokat KM: Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. <i>Nat Rev Drug Discov.</i> 2016; <b>15</b>(11): 771–85. <a target=xrefwindow id=d15181e3580 href="http://www.ncbi.nlm.nih.gov/pubmed/27469033">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3583 href="http://dx.doi.org/10.1038/nrd.2016.139">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726585199">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d15181e3596 class=n-a></a>Papke B, Murarka S, Vogel HA, <i> et al.</i>: Identification of pyrazolopyridazinones as PDEδ inhibitors. <i>Nat Commun.</i> 2016; <b>7</b>: 11360. <a target=xrefwindow id=d15181e3607 href="http://www.ncbi.nlm.nih.gov/pubmed/27094677">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3610 href="http://dx.doi.org/10.1038/ncomms11360">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4843002">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726061265"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3623 class=n-a></a>Patricelli MP, Janes MR, Li LS, <i> et al.</i>: Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. <i>Cancer Discov.</i> 2016; <b>6</b>(3): 316–29. <a target=xrefwindow id=d15181e3634 href="http://www.ncbi.nlm.nih.gov/pubmed/26739882">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3637 href="http://dx.doi.org/10.1158/2159-8290.CD-15-1105">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726061265">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d15181e3650 class=n-a></a>Cetin M, Evenson WE, Gross GG, <i> et al.</i>: RasIns: genetically encoded intrabodies of activated Ras proteins. <i>J Mol Biol.</i> 2017; <b>429</b>(4): 562–73. <a target=xrefwindow id=d15181e3661 href="http://www.ncbi.nlm.nih.gov/pubmed/27865780">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3664 href="http://dx.doi.org/10.1016/j.jmb.2016.11.008">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d15181e3674 class=n-a></a>Kauke MJ, Traxlmayr MW, Parker JA, <i> et al.</i>: An engineered protein antagonist of K-Ras/B-Raf interaction. <i>Sci Rep.</i> 2017; <b>7</b>(1): 5831. <a target=xrefwindow id=d15181e3685 href="http://www.ncbi.nlm.nih.gov/pubmed/28724936">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3688 href="http://dx.doi.org/10.1038/s41598-017-05889-7">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3692 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5517481">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d15181e3701 class=n-a></a>Keeton AB, Salter EA, Piazza GA: The RAS-effector interaction as a drug target. <i>Cancer Res.</i> 2017; <b>77</b>(2): 221–6. <a target=xrefwindow id=d15181e3709 href="http://www.ncbi.nlm.nih.gov/pubmed/28062402">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3712 href="http://dx.doi.org/10.1158/0008-5472.CAN-16-0938">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3715 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5243175">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727224221"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3724 class=n-a></a>Martín-Gago P, Fansa EK, Klein CH, <i> et al.</i>: A PDE6δ-KRas inhibitor chemotype with up to seven H-Bonds and picomolar affinity that prevents efficient inhibitor release by Arl2. <i>Angew Chem Int Ed Engl.</i> 2017; <b>56</b>(9): 2423–8. <a target=xrefwindow id=d15181e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/28106325">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3738 href="http://dx.doi.org/10.1002/anie.201610957">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727224221">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d15181e3751 class=n-a></a>Martín-Gago P, Fansa EK, Winzker M, <i> et al.</i>: Covalent protein labeling at glutamic acids. <i>Cell Chem Biol.</i> 2017; <b>24</b>(5): 589–597.e5. <a target=xrefwindow id=d15181e3762 href="http://www.ncbi.nlm.nih.gov/pubmed/28434875">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3765 href="http://dx.doi.org/10.1016/j.chembiol.2017.03.015">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727639338"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3774 class=n-a></a>Novotny CJ, Hamilton GL, McCormick F, <i> et al.</i>: Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. <i>ACS Chem Biol.</i> 2017; <b>12</b>(7): 1956–62. <a target=xrefwindow id=d15181e3785 href="http://www.ncbi.nlm.nih.gov/pubmed/28530791">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3788 href="http://dx.doi.org/10.1021/acschembio.7b00374">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727639338">F1000 Recommendation</a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727719948"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3801 class=n-a></a>Ross SJ, Revenko AS, Hanson LL, <i> et al.</i>: Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. <i>Sci Transl Med.</i> 2017; <b>9</b>(394): pii: eaal5253. <a target=xrefwindow id=d15181e3812 href="http://www.ncbi.nlm.nih.gov/pubmed/28615361">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3815 href="http://dx.doi.org/10.1126/scitranslmed.aal5253">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727719948">F1000 Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d15181e3829 class=n-a></a>Sakamoto K, Kamada Y, Sameshima T, <i> et al.</i>: K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. <i>Biochem Biophys Res Commun.</i> 2017; <b>484</b>(3): 605–11. <a target=xrefwindow id=d15181e3840 href="http://www.ncbi.nlm.nih.gov/pubmed/28153726">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3843 href="http://dx.doi.org/10.1016/j.bbrc.2017.01.147">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726936958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3852 class=n-a></a>Spencer-Smith R, Koide A, Zhou Y, <i> et al.</i>: Inhibition of RAS function through targeting an allosteric regulatory site. <i>Nat Chem Biol.</i> 2017; <b>13</b>(1): 62–8. <a target=xrefwindow id=d15181e3863 href="http://www.ncbi.nlm.nih.gov/pubmed/27820802">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3866 href="http://dx.doi.org/10.1038/nchembio.2231">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3870 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5193369">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726936958">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727343120"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3883 class=n-a></a>Welsch ME, Kaplan A, Chambers JM, <i> et al.</i>: Multivalent small-molecule pan-RAS inhibitors. <i>Cell.</i> 2017; <b>168</b>(5): 878–889.e29. <a target=xrefwindow id=d15181e3894 href="http://www.ncbi.nlm.nih.gov/pubmed/28235199">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3897 href="http://dx.doi.org/10.1016/j.cell.2017.02.006">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3901 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5362268">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727343120">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13484089"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3914 class=n-a></a>Chandra A, Grecco HE, Pisupati V, <i> et al.</i>: The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. <i>Nat Cell Biol.</i> 2011; <b>14</b>(2): 148–58. <a target=xrefwindow id=d15181e3925 href="http://www.ncbi.nlm.nih.gov/pubmed/22179043">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3928 href="http://dx.doi.org/10.1038/ncb2394">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13484089">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d15181e3941 class=n-a></a>Hong DS, Cabanillas ME, Wheler J, <i> et al.</i>: Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(4): 997–1005. <a target=xrefwindow id=d15181e3952 href="http://www.ncbi.nlm.nih.gov/pubmed/21289252">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3955 href="http://dx.doi.org/10.1210/jc.2010-1899">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3959 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3070247">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d15181e3968 class=n-a></a>Lam ET, Ringel MD, Kloos RT, <i> et al.</i>: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. <i>J Clin Oncol.</i> 2010; <b>28</b>(14): 2323–30. <a target=xrefwindow id=d15181e3979 href="http://www.ncbi.nlm.nih.gov/pubmed/20368568">PubMed Abstract </a> | <a target=xrefwindow id=d15181e3982 href="http://dx.doi.org/10.1200/JCO.2009.25.0068">Publisher Full Text </a> | <a target=xrefwindow id=d15181e3986 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2881718">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717948504"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e3996 class=n-a></a>Brahmer JR, Tykodi SS, Chow LQ, <i> et al.</i>: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(26): 2455–65. <a target=xrefwindow id=d15181e4007 href="http://www.ncbi.nlm.nih.gov/pubmed/22658128">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4010 href="http://dx.doi.org/10.1056/NEJMoa1200694">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4014 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3563263">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717948504">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717548111"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4027 class=n-a></a>Topalian SL, Hodi FS, Brahmer JR, <i> et al.</i>: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(26): 2443–54. <a target=xrefwindow id=d15181e4038 href="http://www.ncbi.nlm.nih.gov/pubmed/22658127">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4041 href="http://dx.doi.org/10.1056/NEJMoa1200690">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4045 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3544539">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717548111">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d15181e4058 class=n-a></a>Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. <i>Science.</i> 2013; <b>342</b>(6165): 1432–3. <a target=xrefwindow id=d15181e4066 href="http://www.ncbi.nlm.nih.gov/pubmed/24357284">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4069 href="http://dx.doi.org/10.1126/science.342.6165.1432">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725419658"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4078 class=n-a></a>Sharma P, Allison JP: The future of immune checkpoint therapy. <i>Science.</i> 2015; <b>348</b>(6230): 56–61. <a target=xrefwindow id=d15181e4086 href="http://www.ncbi.nlm.nih.gov/pubmed/25838373">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4089 href="http://dx.doi.org/10.1126/science.aaa8172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725419658">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727215077"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4102 class=n-a></a>Chen DS, Mellman I: Elements of cancer immunity and the cancer-immune set point. <i>Nature.</i> 2017; <b>541</b>(7637): 321–30. <a target=xrefwindow id=d15181e4110 href="http://www.ncbi.nlm.nih.gov/pubmed/28102259">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4113 href="http://dx.doi.org/10.1038/nature21349">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727215077">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d15181e4126 class=n-a></a>French JD, Bible K, Spitzweg C, <i> et al.</i>: Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes Endocrinol.</i> 2017; <b>5</b>(6): 469–81. <a target=xrefwindow id=d15181e4137 href="http://www.ncbi.nlm.nih.gov/pubmed/27773653">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4140 href="http://dx.doi.org/10.1016/S2213-8587(16)30277-7">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d15181e4150 class=n-a></a>Bongiovanni M, Rebecchini C, Saglietti C, <i> et al.</i>: Very low expression of PD-L1 in medullary thyroid carcinoma. <i>Endocr Relat Cancer.</i> 2017; <b>24</b>(6): L35–L38. <a target=xrefwindow id=d15181e4161 href="http://www.ncbi.nlm.nih.gov/pubmed/28420659">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4164 href="http://dx.doi.org/10.1530/ERC-17-0104">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4168 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5457503">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725249075"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4177 class=n-a></a>Herbst RS, Soria JC, Kowanetz M, <i> et al.</i>: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature.</i> 2014; <b>515</b>(7528): 563–7. <a target=xrefwindow id=d15181e4188 href="http://www.ncbi.nlm.nih.gov/pubmed/25428504">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4191 href="http://dx.doi.org/10.1038/nature14011">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4195 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4836193">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725249075">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725388762"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4208 class=n-a></a>Rizvi NA, Hellmann MD, Snyder A, <i> et al.</i>: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science.</i> 2015; <b>348</b>(6230): 124–8. <a target=xrefwindow id=d15181e4219 href="http://www.ncbi.nlm.nih.gov/pubmed/25765070">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4222 href="http://dx.doi.org/10.1126/science.aaa1348">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4226 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4993154">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725388762">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d15181e4239 class=n-a></a>Schott M, Feldkamp J, Klucken M, <i> et al.</i>: Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. <i>Cancer Immunol Immunother.</i> 2002; <b>51</b>(11–12): 663–8. <a target=xrefwindow id=d15181e4250 href="http://www.ncbi.nlm.nih.gov/pubmed/12439612">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4253 href="http://dx.doi.org/10.1007/s00262-002-0325-z">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d15181e4262 class=n-a></a>Papewalis C, Wuttke M, Seissler J, <i> et al.</i>: Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. <i>Clin Cancer Res.</i> 2008; <b>14</b>(13): 4298–305. <a target=xrefwindow id=d15181e4273 href="http://www.ncbi.nlm.nih.gov/pubmed/18594013">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4276 href="http://dx.doi.org/10.1158/1078-0432.CCR-08-0587">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d15181e4285 class=n-a></a>Wuttke M, Papewalis C, Meyer Y, <i> et al.</i>: Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma. <i>Endocrinology.</i> 2008; <b>149</b>(11): 5627–34. <a target=xrefwindow id=d15181e4296 href="http://www.ncbi.nlm.nih.gov/pubmed/18617610">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4299 href="http://dx.doi.org/10.1210/en.2008-0631">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d15181e4309 class=n-a></a>Bachleitner-Hofmann T, Friedl J, Hassler M, <i> et al.</i>: Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. <i>Oncol Rep.</i> 2009; <b>21</b>(6): 1585–92. <a target=xrefwindow id=d15181e4320 href="http://www.ncbi.nlm.nih.gov/pubmed/19424640">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4323 href="http://dx.doi.org/10.3892/or_00000391">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13096956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4332 class=n-a></a>Kalos M, Levine BL, Porter DL, <i> et al.</i>: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. <i>Sci Transl Med.</i> 2011; <b>3</b>(95): 95ra73. <a target=xrefwindow id=d15181e4343 href="http://www.ncbi.nlm.nih.gov/pubmed/21832238">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4346 href="http://dx.doi.org/10.1126/scitranslmed.3002842">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4350 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3393096">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13096956">F1000 Recommendation</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d15181e4363 class=n-a></a>Rosenberg SA, Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. <i>Science.</i> 2015; <b>348</b>(6230): 62–8. <a target=xrefwindow id=d15181e4371 href="http://www.ncbi.nlm.nih.gov/pubmed/25838374">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4374 href="http://dx.doi.org/10.1126/science.aaa4967">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d15181e4383 class=n-a></a>Porter DL, Hwang W, Frey NV, <i> et al.</i>: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Sci Transl Med.</i> 2015; <b>7</b>(303): 303ra139. <a target=xrefwindow id=d15181e4394 href="http://www.ncbi.nlm.nih.gov/pubmed/26333935">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4397 href="http://dx.doi.org/10.1126/scitranslmed.aac5415">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d15181e4406 class=n-a></a>Johnson LA, June CH: Driving gene-engineered T cell immunotherapy of cancer. <i>Cell Res.</i> 2017; <b>27</b>(1): 38–58. <a target=xrefwindow id=d15181e4414 href="http://www.ncbi.nlm.nih.gov/pubmed/28025979">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4417 href="http://dx.doi.org/10.1038/cr.2016.154">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4420 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5223234">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d15181e4429 class=n-a></a>NetMHC 3.4. <a target=xrefwindow id=d15181e4431 href="http://www.cbs.dtu.dk/services/NetMHC-3.4/">Reference Source</a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d15181e4441 class=n-a></a>Plaza-Menacho I, Burzynski GM, de Groot JW, <i> et al.</i>: Current concepts in RET-related genetics, signaling and therapeutics. <i>Trends Genet.</i> 2006; <b>22</b>(11): 627–36. <a target=xrefwindow id=d15181e4452 href="http://www.ncbi.nlm.nih.gov/pubmed/16979782">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4455 href="http://dx.doi.org/10.1016/j.tig.2006.09.005">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d15181e4464 class=n-a></a>Runeberg-Roos P, Saarma M: Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. <i>Ann Med.</i> 2007; <b>39</b>(8): 572–80. <a target=xrefwindow id=d15181e4472 href="http://www.ncbi.nlm.nih.gov/pubmed/17934909">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4475 href="http://dx.doi.org/10.1080/07853890701646256">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d15181e4484 class=n-a></a>Linette GP, Stadtmauer EA, Maus MV, <i> et al.</i>: Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. <i>Blood.</i> 2013; <b>122</b>(6): 863–71. <a target=xrefwindow id=d15181e4495 href="http://www.ncbi.nlm.nih.gov/pubmed/23770775">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4498 href="http://dx.doi.org/10.1182/blood-2013-03-490565">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4502 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3743463">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d15181e4511 class=n-a></a>Morgan RA, Chinnasamy N, Abate-Daga D, <i> et al.</i>: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. <i>J Immunother.</i> 2013; <b>36</b>(2): 133–51. <a target=xrefwindow id=d15181e4522 href="http://www.ncbi.nlm.nih.gov/pubmed/23377668">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4525 href="http://dx.doi.org/10.1097/CJI.0b013e3182829903">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4529 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3581823">Free Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726038165"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4538 class=n-a></a>Wang QJ, Yu Z, Griffith K, <i> et al.</i>: Identification of T-cell receptors targeting KRAS-mutated human tumors. <i>Cancer Immunol Res.</i> 2016; <b>4</b>(3): 204–14. <a target=xrefwindow id=d15181e4549 href="http://www.ncbi.nlm.nih.gov/pubmed/26701267">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4552 href="http://dx.doi.org/10.1158/2326-6066.CIR-15-0188">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4556 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4775432">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726038165">F1000 Recommendation</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d15181e4569 class=n-a></a>Saunders LR, Bankovich AJ, Anderson WC, <i> et al.</i>: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells <i>in vivo</i>. <i>Sci Transl Med.</i> 2015; <b>7</b>(302): 302ra136. <a target=xrefwindow id=d15181e4583 href="http://www.ncbi.nlm.nih.gov/pubmed/26311731">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4587 href="http://dx.doi.org/10.1126/scitranslmed.aac9459">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4590 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4934375">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d15181e4600 class=n-a></a>Saunders LR, Williams SA, Bheddah S, <i> et al.</i>: Abstract 3093: expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC). <i>Proc Amer Assoc for Cancer Res.</i> 2017; <b>7</b>(13 Suppl): Abstract 3093. <a target=xrefwindow id=d15181e4611 href="http://dx.doi.org/10.1158/1538-7445.AM2017-3093">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727089160"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4620 class=n-a></a>Rudin CM, Pietanza MC, Bauer TM, <i> et al.</i>: Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncol.</i> 2017; <b>18</b>(1): 42–51. <a target=xrefwindow id=d15181e4631 href="http://www.ncbi.nlm.nih.gov/pubmed/27932068">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4634 href="http://dx.doi.org/10.1016/S1470-2045(16)30565-4">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4638 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5481162">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727089160">F1000 Recommendation</a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727600493"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4651 class=n-a></a>Shin SM, Choi DK, Jung K, <i> et al.</i>: Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. <i>Nat Commun.</i> 2017; <b>8</b>: 15090. <a target=xrefwindow id=d15181e4662 href="http://www.ncbi.nlm.nih.gov/pubmed/28489072">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4665 href="http://dx.doi.org/10.1038/ncomms15090">Publisher Full Text </a> | <a target=xrefwindow id=d15181e4669 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5436137">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727600493">F1000 Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727194330"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15181e4682 class=n-a></a>Strosberg J, El-Haddad G, Wolin E, <i> et al.</i>: Phase 3 Trial of <sup>177</sup>Lu-dotatate for midgut neuroendocrine tumors. <i>N Engl J Med.</i> 2017; <b>376</b>(2): 125–35. <a target=xrefwindow id=d15181e4696 href="http://www.ncbi.nlm.nih.gov/pubmed/28076709">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4700 href="http://dx.doi.org/10.1056/NEJMoa1607427">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727194330">F1000 Recommendation</a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d15181e4713 class=n-a></a>Waldherr C, Schumacher T, Pless M, <i> et al.</i>: Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. <i>Nucl Med Commun.</i> 2001; <b>22</b>(6): 673–8. <a target=xrefwindow id=d15181e4724 href="http://www.ncbi.nlm.nih.gov/pubmed/11403179">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4727 href="http://dx.doi.org/10.1097/00006231-200106000-00011">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d15181e4736 class=n-a></a>Bodei L, Handkiewicz-Junak D, Grana C, <i> et al.</i>: Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. <i>Cancer Biother Radiopharm.</i> 2004; <b>19</b>(1): 65–71. <a target=xrefwindow id=d15181e4747 href="http://www.ncbi.nlm.nih.gov/pubmed/15068613">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4750 href="http://dx.doi.org/10.1089/108497804773391694">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d15181e4760 class=n-a></a>Makis W, McCann K, McEwan AJ: Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases. <i>Clin Nucl Med.</i> 2015; <b>40</b>(5): 408–12. <a target=xrefwindow id=d15181e4768 href="http://www.ncbi.nlm.nih.gov/pubmed/25674858">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4771 href="http://dx.doi.org/10.1097/RLU.0000000000000706">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d15181e4780 class=n-a></a>Vaisman F, Rosado de Castro PH, Lopes FP, <i> et al.</i>: Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? <i>Clin Nucl Med.</i> 2015; <b>40</b>(2): 123–7. <a target=xrefwindow id=d15181e4791 href="http://www.ncbi.nlm.nih.gov/pubmed/25546220">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4794 href="http://dx.doi.org/10.1097/RLU.0000000000000628">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d15181e4803 class=n-a></a>Salavati A, Puranik A, Kulkarni HR, <i> et al.</i>: Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. <i>Semin Nucl Med.</i> 2016; <b>46</b>(3): 215–24. <a target=xrefwindow id=d15181e4814 href="http://www.ncbi.nlm.nih.gov/pubmed/27067502">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4817 href="http://dx.doi.org/10.1053/j.semnuclmed.2016.01.010">Publisher Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d15181e4826 class=n-a></a>Conry BG, Papathanasiou ND, Prakash V, <i> et al.</i>: Comparison of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. <i>Eur J Nucl Med Mol Imaging.</i> 2010; <b>37</b>(1): 49–57. <a target=xrefwindow id=d15181e4844 href="http://www.ncbi.nlm.nih.gov/pubmed/19662413">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4847 href="http://dx.doi.org/10.1007/s00259-009-1204-z">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d15181e4856 class=n-a></a>Treglia G, Castaldi P, Villani MF, <i> et al.</i>: Comparison of 18F-DOPA, <sup>18</sup>F-FDG and <sup>68</sup>Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. <i>Eur J Nucl Med Mol Imaging.</i> 2012; <b>39</b>(4): 569–80. <a target=xrefwindow id=d15181e4874 href="http://www.ncbi.nlm.nih.gov/pubmed/22223169">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4877 href="http://dx.doi.org/10.1007/s00259-011-2031-6">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d15181e4886 class=n-a></a>Ozkan ZG, Kuyumcu S, Uzum AK, <i> et al.</i>: Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. <i>Nucl Med Commun.</i> 2015; <b>36</b>(3): 242–50. <a target=xrefwindow id=d15181e4897 href="http://www.ncbi.nlm.nih.gov/pubmed/25369749">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4900 href="http://dx.doi.org/10.1097/MNM.0000000000000240">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d15181e4910 class=n-a></a>Tran K, Khan S, Taghizadehasl M, <i> et al.</i>: Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. <i>Hell J Nucl Med.</i> 2015; <b>18</b>(1): 19–24. <a target=xrefwindow id=d15181e4921 href="http://www.ncbi.nlm.nih.gov/pubmed/25679074">PubMed Abstract </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d15181e4930 class=n-a></a>Herac M, Niederle B, Raderer M, <i> et al.</i>: Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. <i>APMIS.</i> 2016; <b>124</b>(10): 839–45. <a target=xrefwindow id=d15181e4941 href="http://www.ncbi.nlm.nih.gov/pubmed/27539746">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4944 href="http://dx.doi.org/10.1111/apm.12584">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d15181e4953 class=n-a></a>Papotti M, Kumar U, Volante M, <i> et al.</i>: Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. <i>Clin Endocrinol (Oxf).</i> 2001; <b>54</b>(5): 641–9. <a target=xrefwindow id=d15181e4964 href="http://www.ncbi.nlm.nih.gov/pubmed/11380495">PubMed Abstract </a> | <a target=xrefwindow id=d15181e4967 href="http://dx.doi.org/10.1046/j.1365-2265.2001.01175.x">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2184.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2184.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD, 21287, USA<br/> <p> <div class=margin-bottom> Barry Nelkin <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-2184/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 28 Dec 2017, 6:2184 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.12645.1">https://doi.org/10.12688/f1000research.12645.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Nelkin B. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=13691 data-id=12645 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12645.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-2184/v1/pdf?article_uuid=ad1ff134-02c6-412a-b0fc-7dc23447bbb3" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.12645.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2184 (<a href="https://doi.org/10.12688/f1000research.12645.1" target=_blank>https://doi.org/10.12688/f1000research.12645.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=12645 id=mobile-track-article-signin-12645 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12645?target=/articles/6-2184.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13691 /> <input name=articleId type=hidden value=12645 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Michael J Demeure</strong>, Program Director for Precision Medicine, Hoag Family Cancer Institute, USA; Adjunct Clinical Professor, Translational Genomics Research Institute, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Robert Gagel</strong>, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2184.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2184.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29169-29170></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=12506-29171></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-2184/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>28 Dec 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Michael J Demeure</strong>, Program Director for Precision Medicine, Hoag Family Cancer Institute, USA; Adjunct Clinical Professor, Translational Genomics Research Institute, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Robert Gagel</strong>, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-2184.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-2184/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the biology and therapy...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2184/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2184/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2184/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Nelkin B');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2184/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-2184",
            templates : {
                twitter : "Recent advances in the biology and therapy of medullary thyroid.... Nelkin B, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-2184/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the biology and therapy of medullary thyroid carcinoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the biology and therapy of medullary thyroid carcinoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/12645/13691")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "13691");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "29170": 0,
                           "29171": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "a78fdaaf-8058-468b-b309-f8256cfe5e6a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2184.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2184.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2184.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-2184.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-2184.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>